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Hcmv Car T Cells As A Novel Platform For Glioblastoma Cancer Immunotherapy 
Abstract 
Glioblastoma multiforme (GBM) is the most common and deadliest primary brain tumor. 
Immunotherapeutic approaches using chimeric antigen receptor (CAR) T cells have shown limited 
efficacy against GBM due to heterogeneous target antigen expression. We hypothesize that human 
cytomegalovirus (HCMV) can serve as a therapeutic target for GBM. HCMV can be detected in up to 90% 
of GBM tumor samples but not the surrounding normal brain tissue. The role of HCMV as a tumor-
promoting virus is poorly understood but its presence in the tumor presents a novel approach to 
developing a therapy for GBM by re-directing T cells to target HCMV. We detected the presence of HCMV 
in GBM tumor samples via IHC and confirmed expression of HCMV gene UL55/glycoprotein B (gB) in 45% 
of primary GBM tumors. A CAR was generated and optimized to recognize the HCMV surface antigen gB. 
In vitro testing of the anti-gB CAR revealed activity against the U87 glioma cell line stably transduced to 
express gB and CMV-infected human foreskin fibroblasts (HFF) cells. In vivo, gB CARs were able to treat 
established GBM tumors in a xenograft mouse model. In vitro co-cultures of gB CAR T cells against the 
human GBM explant, D270, demonstrated tumor recognition and anti-tumor function against primary 
GBM. gB CAR T cells were able to control D270 tumor growth in vivo despite undetectable levels of 
antigen expression. Mice displaying stable disease showed improved persistence of engrafted human T 
cells and tumor infiltration. These results suggest that CAR T cells may be effective in recognizing 
extremely low abundance antigens, and taken together, the results of this study show the feasibility of 
using gB CAR T cells as a platform to target HCMV in GBM tumors to treat patients with GBM. Ultimately, 
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Glioblastoma multiforme (GBM) is the most common and deadliest primary brain 
tumor. Immunotherapeutic approaches using chimeric antigen receptor (CAR) T 
cells have shown limited efficacy against GBM due to heterogeneous target 
antigen expression. We hypothesize that human cytomegalovirus (HCMV) can 
serve as a therapeutic target for GBM. HCMV can be detected in up to 90% of 
GBM tumor samples but not the surrounding normal brain tissue. The role of 
HCMV as a tumor-promoting virus is poorly understood but its presence in the 
tumor presents a novel approach to developing a therapy for GBM by re-directing 
T cells to target HCMV. We detected the presence of HCMV in GBM tumor 
samples via IHC and confirmed expression of HCMV gene UL55/glycoprotein B 
(gB) in 45% of primary GBM tumors. A CAR was generated and optimized to 
recognize the HCMV surface antigen gB. In vitro testing of the anti-gB CAR 
revealed activity against the U87 glioma cell line stably transduced to express gB 
and CMV-infected human foreskin fibroblasts (HFF) cells. In vivo, gB CARs were 
able to treat established GBM tumors in a xenograft mouse model. In vitro co-
cultures of gB CAR T cells against the human GBM explant, D270, demonstrated 
tumor recognition and anti-tumor function against primary GBM. gB CAR T cells 
were able to control D270 tumor growth in vivo despite undetectable levels of 
antigen expression. Mice displaying stable disease showed improved persistence 
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of engrafted human T cells and tumor infiltration. These results suggest that CAR 
T cells may be effective in recognizing extremely low abundance antigens, and 
taken together, the results of this study show the feasibility of using gB CAR T cells 
as a platform to target HCMV in GBM tumors to treat patients with GBM. Ultimately, 
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Glioblastoma (GBM) is a highly lethal and intractable brain tumor with few 
therapeutic options. Recognized as a stage IV brain tumor by the World Health 
Organization (WHO), GBM is the most aggressive and most frequent form of brain 
cancer (Cheray et al., 2017; Wen & Kesari, 2008). GBM can develop in two forms. 
The first form of GBM arises spontaneously, typically in the elderly, and with no 
prior evidence of disease. Secondary GBMs arise from low-grade gliomas and 
eventually manifest into high-grade GBM. Unlike primary GBMs, the secondary 
form of GBM is less aggressive and presents with a better prognosis for the patient. 
This distinction is important as much of the therapeutic interventions used to treat 
patients with GBM are determined by the primary or secondary origin of the tumor 
(Lombardi & Assem, 2017). It is estimated that of the 14,000 cases of brain tumors 
diagnosed annually in the United States, GBM will account for 60-70% of new brain 
tumor cases (Wen & Kesari, 2008). Current standard of care for GBMs consist of 
maximal surgical resection of the tumor followed by concomitant chemotherapy 
and radiotherapy (Stupp et al., 2005). Even with the most recent additions to 
standard of care, GBM offers a grim prognosis with a median life expectancy of 
approximately 15 months after clinical intervention. Invariably, the tumor will recur 
in most patients, resulting in less than 10% of patients surviving up to 5 years 
(Stupp et al., 2005). The shortcoming of standard cancer treatment modalities is 
the non-specific nature by which these therapies target both malignant and non-
malignant tissues (Phillips et al., 2006; Wen & Kesari, 2008). 
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No known risk factors have been associated with GBM tumors and the cell 
of origin for primary GBMs remains controversial. Unlike secondary GBM that 
stems from a known precursor cell, primary GBM has no known cell of origin 
(Alcantara Llaguno & Parada, 2016). Characterization of molecular pathways 
altered within individual GBM tumors has helped define treatment options and 
predict patient prognosis. Expression profiles based on common oncogenic 
pathways found in GBMs have distinguished GBM into four molecular subtypes: 
1) Classical, 2) Mesenchymal, 3) Proneural, and 4) Neural (Cheray et al., 2017; 
Verhaak et al., 2010). Despite advances in basic understanding of the drivers of 
GBM, the disease remains intractable to clinical interventions and has a large 
unmet clinical need for improvements to the current standard of care (Stupp et al., 
2005).  
 
Standard cancer therapies and the development of immunotherapies:  
Standard forms of cancer treatment, such as surgical resection, 
radiotherapy, and chemotherapy, are often imprecise in directly targeting the 
tumor; this results in a range of side effects that damage normal cells in addition 
to malignant cells (Phillips et al., 2006; Wen & Kesari, 2008). Improving the 
specificity of new class of drugs to precisely target the cancer cell will invariably 
help mitigate the side effects associated with standard forms of cancer treatment. 
In the last two decades, new classes of oncology drugs have emerged with the 
aim of specifically targeting the tumor. Small molecular inhibitors are 
pharmacological agents that interrupt the activity of proteins involved in driving 
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tumor growth. One of the first FDA approved targeted agents was Gleevec 
(Imatinib). Gleevec inhibits the aberrantly active fusion protein BCR-ABL that 
results from the genetic translocation of the Philadelphia chromosome. This 
therapy is capable of turning a life-threatening disease, chronic myeloid leukemia 
(CML), into a manageable one with a daily dose. However, Gleevec represents 
just one small success story in field of small molecular inhibitors (Deininger, 
Buchdunger, & Druker, 2005). More often than not, cancers develop resistance to 
targeted pathways over the course of treatment. Patients treated with Gleevec are 
prescribed second line drugs that combat CML when the disease develops 
resistance to the drug of the initial treatment (Rosti, Castagnetti, Gugliotta, & 
Baccarani, 2017). The use of targeted agents in oncology parallels the story of 
antibiotic use in infectious disease. Resistance mechanisms rapidly emerge, 
rendering new drugs infective against a dynamically evolving tumor. 
 On a similar trajectory, the development of cancer immunotherapies stem 
from basic understanding of the immune system. One of the earliest forms of 
experimental cancer immunotherapies was the use of high-dose human IL-2 at the 
National Cancer Institute (NCI) to boost immune responses against melanoma 
(Rosenberg et al., 1988). The use of exogenously administered molecules to 
manipulate a patient’s immune system to attacking tumor cells forms that basis of 
many of the immunotherapies currently being developed. Monoclonal antibodies 
(mAb) targeting oncogenic proteins often amplified on the surface of tumor cells 
were some of the first clinically approved forms of cancer immunotherapy (Weiner, 
Surana, & Wang, 2010). Combining the potency of the immune system with a 
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refined focus on specific drivers of cancer growth resulted in new forms of drugs 
that offered greater precision than standard of forms of cancer treatment. 
Exemplifying this type of therapeutic is Trastuzumab (Herceptin), which is a mAb 
that selectively inhibits the function of oncogenic HER2 protein and is used in the 
treatment of breast cancer. Shifting the focus from targets on a cancer cell to 
targets found on T cells marked a turning point in mAb-based therapies. 
Checkpoint blockade immunotherapies (CBI) remove brakes that hinder the ability 
of the immune system to recognize malignant cells and mount an immune 
response to antigens found within a tumor (Wei, Duffy, & Allison, 2018). The ability 
to unleash the immune system upon a tumor with the administration of a CBI is a 
powerful tool that brought cancer immunotherapies to the forefront as a new 
treatment modality in oncology. Unlike traditional cancer therapies, 
immunotherapies do not directly target the tumor; instead, these drugs 
predominately work on the T cells that are poised to attack a tumor but may be 
limited by tumor-intrinsic immunosuppressive mechanisms. 
The targeted therapies outlined above are off-the-shelf therapies that can 
be administered to any patient with tumors amenable to treatment, oncogene 
inhibition or immune targeting. Concomitant with the development of these 
immunotherapies has been the development of new experimental and highly 
personalized T cell-based immunotherapies. Adoptive cell transfer (ACT) of ex vivo 
expanded T cells is not off-the-shelf in its current form but instead offers the benefit 
of delivering a more dynamic “living drug” with pharmacokinetics that allows the 
therapy to work in the patient for years beyond a single dose (Kalos & June, 2013).  
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The Immune system and Cancer:  
The development of ACT therapies stems from observations that the 
immune system can have anti-tumor activity. This relationship is complicated by 
the double-edged roles the immune system can play in the development of a 
tumor. On one hand, tumors are able to subvert immune responses by coopting 
immunosuppressive cells and mechanisms the immune system utilizes to prevent 
autoimmunity. On the other hand, the immune system can readily recognize 
tumors that have deviated from normal tissues as a foreign threat. The evolution 
of a tumor and its relationship to the immune system is reflected in the theory of 
cancer immunoediting (Mittal, Gubin, Schreiber, & Smyth, 2014). The growth of a 
nascent tumor can be broken down into three phases. First, in the elimination 
phase, the most immunogenic tumor cells are selectively deleted from the tumor 
mass by anti-tumor T cells. This process can occur over years, eventually 
establishing an equilibrium phase between the anti-tumor T cells and the 
immunosuppressive cells or molecules that the tumor uses to shutdown anti-tumor 
immune responses. Ultimately, this immunological détente is broken, resulting in 
the final phase of tumor escape. The end result of this process is a tumor mass 
virtually invisible to the immune system due to loss tumor of immunogenicity and/or 
the development of an immunosuppressive tumor microenvironment (Mittal et al., 
2014). Understanding the relationship between a developing tumor and the 
immune system offers pathways that can be targeted as a mode of therapeutic 
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intervention. Cancer immunotherapies exploit the natural ability of T cells to 
recognize tumor cells and help tip the balance in favor of an anti-tumor response.  
 
Adoptive T cell therapies for cancer: 
The clinical use of cell therapies to treat human cancer is relatively new. 
The lab of Steven Rosenberg pioneered the use of tumor infiltrating lymphocytes 
(TIL) therapy. TIL are T cells that have trafficked to the tumor due to their ability to 
respond to an antigen presented by the tumor. These T cells are harvested from 
resected tumors and expanded ex vivo for ACT therapy. The NCI group has 
improved upon the ACT platform by incorporating a lymphodepletion regimen prior 
to TIL transfer in order to enhance engraftment of the newly introduced T cells 
(Rosenberg & Restifo, 2015). TIL therapies do not depend on identifying T cell 
specificities, instead by virtue of tumor residency all TILs were initially regarded as 
tumor reactive. TIL therapies rely on the existence of tumor-infiltrative and reactive 
T cells that can be expanded ex vivo. Melanoma is a particularly good model for 
TIL therapy, as these type of tumors are considered immunologically “hot” due to 
the high prevalence of neo-antigens that T cells can recognize (Schumacher & 
Schreiber, 2015). However, unlike melanoma, most tumors do not exhibit high 
mutational loads and may not contain pools of TILs for therapeutic intervention 
(Alexandrov et al., 2013). This limitation sparked a shift from expanding naturally 
occurring T cells found within a tumor to re-directing polyclonal T cells from the 
periphery to recognize tumor antigen via gene-transfer. 
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T cells could be re-directed to recognize tumor antigens via gene-transfer 
of an isolated TCR of known specificity (Dembic et al., 1986). Though this method, 
rare T cell clones found in a polyclonal TIL population can be reproduced on a 
larger scale as immunodominant effectors via TCR transduction of polyclonal 
peripheral blood T cells. This was demonstrated in a clinical trial using T cells re-
directed to the melanoma antigen MART-1 (Johnson et al., 2009; Morgan et al., 
2006). Other groups have followed suit by re-directing T cells to NY-ESO-1 in 
synovial sarcoma, leading to clinical objective responses in half of the patient 
cohort (Robbins et al., 2011). Using TCR gene-transfer to re-direct T cell specificity 
does have its limitations. TCRs require an exact match between a patient’s human 
leukocyte antigen (HLA) and the TCR alpha (a) and beta (b) chains. If a patient 
does not share the same HLA-allele that the TCR recognizes, this therapy would 
not benefit the patient. Newer technologies bypass this limitation by re-directing T 
cells with gene transfer of synthetic molecules, CARs, which are designed in an 
HLA-independent manner. 
 
Chimeric Antigen Receptor Design: 
Unlike TCRs, CARs are synthetic gene constructs that incorporate domains 
from different molecules into one elegant and modular design (Kalos & June, 
2013). The design of a CAR can be roughly broken down into three domains. The 
first is the recognition motif that allows detection of the surface antigen. Second is 
the hinge or spacer region that affects that ability of a T cell to recognize their 
cognate antigen. The last domain is the signaling domain that modulates and 
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allows for signal transduction upon ligation of the target antigen. The modular 
design of CAR molecules allows for rapid development of new CARs with novel 
specificities, each of which must be tested empirically in order to identify the lead 
construct. Because CAR T cells recognize antigen in a different fashion from 
TCRs, the biophysical interaction between a CAR T cell and target cell have also 
been altered (reviewed in Sharma and Kranz (2016)). Therefore, special 
considerations must be paid to the structure and expression of the target antigen 
and how these factors can influence CAR T cell effectiveness against a tumor cell. 
The remainder of this section will expand on the contribution of the three domains 
of a CAR molecule and how they can be used to guide CAR design (Kalos & June, 
2013; Sadelain, Brentjens, & Riviere, 2013).  
The recognition domain of a CAR construct confers a new specificity to a 
re-directed T cell. The ease of selecting a new specificity for CAR T cells is only 
limited by the expression of a target antigen on the surface of a cell. The most 
commonly used form of a recognition domain is based on a single chain variable 
fragment (scFv). ScFvs incorporate the variable regions of a monoclonal antibody 
and their specificity onto the signaling apparatus of the artificial T cell receptor. 
Moreover, the variable heavy and light chains can be swapped in orientation, which 
may change the sensitivity of the CAR to the target antigen (Burns et al., 2010). 
The recognition domain of a CAR can take on other forms like the natural ligand 
for a particular tumor antigen. This approach was utilized in the design of a 
“zetakines” targeting IL13RA2 in GBM, in which IL13 ligand was incorporated as 
the recognition domain of the CAR (Kahlon et al., 2004). The most recent approach 
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to the alteration of the CAR recognition domain comes in the form of chimeric 
autoantibody receptors (CAARs). CAARs fuse the target antigen of autoreactive B 
cells to selectively target those specific B cells for destruction. This approach was 
first published in a model of pemphigus vulgaris, where autoreactive B cells react 
to desmoglein 3 (Dsg3) (Ellebrecht et al., 2016). The specificity conferred by the 
recognition domain of CAR molecule warrants important consideration as it can 
directly contribute to off-target toxicities associated with CAR T cell therapies 
(reviewed in Antigen Selection and Safety considerations).  
The hinge or spacer domain influences the manner in which the CAR T cell 
interacts with the target antigen. It is this domain that connects the recognition 
domain to the signaling domains and allows for fine-tuning of the sensitivity of the 
CAR to its cognate antigen (Ellebrecht et al., 2016; N. Watanabe et al., 2016; Ying 
et al., 2019). To illustrate the importance of the hinge domain, CARs were 
designed to recognize the tumor-associated antigen ROR1 based on two 
monoclonal antibodies targeting two different epitopes. The antibody epitopes 
were found to be either membrane proximal or on the apex of the ROR1 molecules, 
i.e. membrane distal. The high affinity anti-ROR1 R12 scFv mapped to a 
membrane proximal epitope on ROR1 and could only be recognized by CAR T 
cells bearing the long hinge variant of IgG4 and not the short, truncated hinge 
variants of IgG4. However, if a CAR construct incorporated the 2A2 scFv, which 
mapped to a membrane distal epitope, the short, truncated hinge was found to 
exhibit optimal T cell effector function in vitro (Hudecek et al., 2013). Moreover, the 
IgG4 hinge was found to have unexpected biological activity: the IgG4 hinge 
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interacted with murine Fc receptors in NSG mouse models (Hudecek et al., 2015). 
This interaction is not entirely unexpected as the IgG4 hinge contains an intact Fc 
portion capable of being engaged by Fc gamma receptors (FcγRs) receptors. This 
biological activity of the spacer domain on CAR T cell performance was initially 
reported in CAR constructs bearing IgG1 derived hinge domain (A. Hombach, 
Hombach, & Abken, 2010). Mutations in the CH2 domain of the IgG4 spacer 
improved the anti-tumor efficacy of the CAR T cells bearing the mutant IgG4 
spacer by reducing activation induced cell death (AICD) (Hudecek et al., 2015; 
Jonnalagadda et al., 2015). 
While the location of the epitope can influence the choice of spacer domain, 
there are no generalizable rules on the design of CAR for a particular target or 
epitope yet. The kinetic segregation model may help explain the relationship 
between the CAR’s design and its ability to recognize target. This model outlines 
a mechanism by which a TCR signals or is inhibited by the spatial segregation of 
negative regulators of TCR signaling, such as the CD45 phosphatase. The large 
ectodomain of CD45 is excluded from the immunological synapse in instances 
where the TCR encounters its cognate antigen in the context of MHC (J. R. James 
& Vale, 2012). The spatial interaction between a T cell and its target remains 
constant for all TCR-MHC junctions, as CD45 is excluded from TCR-MHC immune 
synapses (Choudhuri, Wiseman, Brown, Gould, & van der Merwe, 2005). On the 
other hand, CAR T cells bearing synthetic receptors can exhibit variability in CD45 
exclusion due to differences in CAR extracellular designs and require additional 
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optimization of the hinge domain for ideal CAR T cell signal transduction (Davis & 
van der Merwe, 2006; Huppa, Gleimer, Sumen, & Davis, 2003). 
The selection of CAR signaling domains can be the most influential aspects 
of CAR T cell function. The first iteration of a CAR originated in the lab of Zelig 
Eschar (Eshhar, Waks, Gross, & Schindler, 1993). The basic design of the “T-
body” fused an extracellular scFv to the CD3z signaling motif. The T-body design 
later became known as a first-generation CAR because it lacked additional co-
stimulatory domains that augment the activation potential of CAR constructs. The 
CD3 z domain is sufficient to re-direct a T cell to perform cytolytic function but 
additional T cell functions require higher levels of stimulation that is provided by 
the incorporation of co-stimulatory domains. CARs that include additional signaling 
domains have led to clinical success and augmented CAR T cell function. Of note 
are the CD28 and 4-1BB (CD137) domains that have been evaluated extensively 
in both preclinical models and in the clinic. Studies comparing the activity of these 
two co-stimulatory domains in CAR T cells have revealed key differences. 
Biochemically, the incorporation of a 4-1BB domain alters a CAR T cell’s metabolic 
programming, promoting fatty acid oxidation and enrichment of a central memory 
phenotype (Kawalekar et al., 2016). This is in contrast to CD28-based CAR T cells, 
which have glycolytic metabolism and an enriched effector phenotype. These 
differences may account for differences in the clinical persistence of CD19 re-
directed CAR T cells, where 4-1BB-based CAR T cells persist longer than those 
based on CD28 (Maude et al., 2014; Park et al., 2018). These comparisons draw 
upon models targeting CD19 antigen, but does this superior activity apply to other 
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models? A GD2-specific CAR with a CD28 co-stimulatory domain was found to 
prematurely exhaust CAR T cells in vitro due to tonic signaling. Exchanging the 
CD28 co-stimulatory domain with 4-1BB diminished the exhaustion of GD2 CAR T 
cells (Long et al., 2015). These studies highlight the biochemical and clinical 
differences of CAR domains. Other co-stimulatory molecules have been evaluated 
in the context of CAR T cells, but it is unknown how they will compare clinically to 
the use of CD28 and 4-1BB. 
 Regardless of the approach undertaken to redirect a CAR T cell to a target 
antigen, optimization of the CAR construct may require several rounds of in vitro 
and in vivo testing in order to identify a lead construct with superior anti-tumor 
activity. 
 
T cell biology: 
Many of the considerations undertaken in the design of a CAR molecule 
draw upon the mechanistic understanding of T cell biology. T cell development, 
activation, and exhaustion inform some of limitations placed upon on a T cell and 
how they can be circumnavigated through the use of synthetic biology.  
The ability of the immune system to recognize and clear foreign antigens 
while sparing endogenous self-antigens forms the first principles of T cell biology: 
the ability to respond to non-self. Selection of T cells occurs in the thymus where 
self-reactive T cells are selectively eliminated in two phases that evaluate the 
ability of a T cell to sense antigen (positive selection) and deletion of T cells that 
respond strongly to self-antigens (negative selection) (Klein, Hinterberger, 
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Wirnsberger, & Kyewski, 2009). This principle is important in cancer 
immunotherapy precisely because tumor cells derived from the same host as the 
immune system occupy a grey area in the self/non-self dichotomy. Chimeric 
antigen receptor (CAR) T cells bypass this natural limitation by re-directing post-
thymic T cells to tumor-associated antigens (self-antigens) that are not exclusively 
expressed on the tumor. Thymic selection of T cells prevents development of 
autoimmunity via deletion of self-reactive T cells (central tolerance) but in turn may 
prevent robust immune recognition of a developing tumor that harbors mutated 
self-antigens (neo-antigens). Immunotherapies often blur the line between a 
normal immune response and autoimmunity to achieve therapeutic ends. This is 
best exemplified by CART19 T cell therapies that indiscriminately recognize CD19 
antigen on both leukemic and normal B cells. CART19 T cell therapy can result in 
complete clearance of leukemic B cells but also leave the patient with B cell 
aplasia, a manageable form of autoimmunity (Grupp et al., 2013; Porter, Levine, 
Kalos, Bagg, & June, 2011).  
 The second basic principle of T cell biology focuses on post-thymic T cell 
activation. Naive T cells that have exited the thymus and have not been exposed 
to their cognate antigen must undergo a carefully controlled process that 
safeguards against inappropriate activation. Canonically, T cells must receive two 
signals in order to be fully activated; failure to acquire both signals would lead to 
an anergic T cell response (Smith-Garvin, Koretzky, & Jordan, 2009). All post-
thymic T cells express a rearranged T cell receptor (TCR) that has been selected 
to respond to a foreign antigen. Engagement of a TCR to its cognate antigen in the 
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form a peptide-MHC complex provides “signal 1” of T cell activation. This signal is 
enhanced by the engagement of additional T cell molecules, known as co-
stimulatory receptors, with ligands expressed on activated antigen presenting 
cells, an event that provides “signal 2”. Co-stimulatory receptors, such as CD28, 
4-1BB, ICOS, and OX40, augment the strength of signal one and allow for full T 
cell activation (Chen & Flies, 2013). It is at this stage that CD8+ cytotoxic T cells 
or CD4+ helper T cells are able to perform their effector functions after 
encountering their cognate antigen once again on foreign, malignant, or infected 
cells. Basic understanding of the molecular mechanism of T cell activation has 
improved the function of CAR molecules and their performance in the clinic. CAR 
molecules bearing only a CD3z chain intracellular motif form the basis of “first 
generation CARs.” These CAR constructs are immunologically equivalent to 
receiving only “signal 1” via TCR engagement of cognate antigen. The addition of 
the intracellular signaling domain from a co-stimulatory molecule in the design of 
second generation CAR constructs has improved the clinical performance of CD19 
CAR T cells (Kalos & June, 2013; Milone et al., 2009; Sadelain et al., 2013). 
 As the basic understanding of T cell biology continues to shed light into new 
targets for immunotherapy, the focus has now shifted to understanding how to 
prevent effector T cells from succumbing to T cell exhaustion. The progressive loss 
of T cell effector function due to chronic antigen stimulation renders anti-tumor T 
cell responses ineffective. Exhausted T cells can also be identified by their 
expression of inhibitory receptors, such as cytotoxic T lymphocyte antigen 4 
(CTLA-4) or programed cell death protein 1 (PD-1) (Wherry & Kurachi, 2015). 
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Blockade of these inhibitory receptors has been the focus of new CBIs that seek 
to ameliorate the effects of exhaustion by blocking these pathways (Wei et al., 
2018). Blockade of CTLA-4 molecule may work by lowering the threshold of 
activation for T cells that may respond to a self-antigen (Fife & Bluestone, 2008), 
widening the window of T cells capable of responding to the tumor. PD-1 and PD-
L1 blockade seeks to reinvigorate T cells that are experiencing exhaustion by 
blocking the signaling pathway that would maintain the exhausted phenotype (Wei 
et al., 2018). CBIs are powerful tools in oncology that can unleash dynamic anti-
tumor responses with an off-the shelf application. However, not all patients may 
respond to CBI therapy. T cell exhaustion may be irreversible in some T cells that 
have been epigenetically reprogrammed to be unresponsive to CBI therapy 
(Pauken et al., 2016). Moreover, tumors that carry low mutational burden may not 
respond to CBI therapies. The positive correlation between a tumor’s mutational 
burden and clinical responses been reported for both PD-1 and CTLA-4 (Rizvi et 
al., 2015; Snyder et al., 2014; Yarchoan, Hopkins, & Jaffee, 2017). Patients that 
do not respond to CBI therapies may benefit from other T cell therapies, such as 
the adoptive transfer of T cells enriched for a certain tumor target specificity. 
 
Antigen Selection and Safety considerations:  
As reviewed in the previous section, the immune system has mechanisms 
of safeguarding against the development of autoimmunity. Many antigens targeted 
by re-directed T cells are derived from self-antigens. For this reason, target antigen 
selection is arguably the most critical consideration in the design of a T cell therapy. 
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The expression and biology of the selected antigen can make the difference 
between a beneficial clinical outcome, autoimmunity, or even death of a patient. 
ACT therapies have a short but telling history of how antigen selection translates 
in the clinic. Broadly, tumor antigens can be categorized as a tumor-associated 
antigen (TAA) or a tumor-specific antigen (TSA). The type of target antigen, TAA 
pr TSA has implications for the clinical activity of re-directed T cells. 
 TAAs represent the risker group of tumor antigens on the basis that their 
expression is not confined exclusively to malignant tissue. Targeting a given TAA 
profile can be acceptable if expressed on non-essential cells or it can have lethal 
consequences if found on vital organs. For example, clinical trials using CAR T 
cells designed with the scFv derived from the monoclonal antibody trastuzumab 
(Herceptin), which targets the TAA HER2, led to the death of a patient due to acute 
“on-target, off-tumor” toxicities in the lungs (Morgan et al., 2010). It bears 
mentioning that while Herceptin is FDA approved with known toxicities, the same 
antibody had greater and unexpected toxicities when expressed in CAR T cells. 
MAGE-A3 is a TAA that belongs a class of antigens known as cancer-testis 
antigens (CTAs). Given the limited expression profile of CTAs, they were thought 
to be safer than other TAAs, but T cells engineered to target MAGE-A3 have led 
to severe adverse events. Two clinical trials in which T cells were re-directed with 
TCRs targeting MAGE-A3 had unforeseen “off-target, off-tumor” toxicities due to 
cross-reactivity. In one trial, re-directed T cells recognized other MAGE-A family 
proteins in brain tissue, which led to the fatality of patients (Morgan et al., 2013). 
In the other trial, which using affinity-enhanced TCRs to target MAGE-A3, a patient 
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developed severe cardio-toxicities when the re-directed T cells cross-reacted with 
the protein titan (Linette et al., 2013). While these complications were not predicted 
before administration of the T cell therapy, there may be ways to mitigate the 
toxicities of redirected T cells responses utilizing new technologies for antigen 
selection. 
The clinical trials outlined above represent some of the more severe 
outcomes associated with ACT of re-directed T cells; other trials have found 
success in targeting TAAs with tolerable toxicities. T cells redirected to MART-1 
using human or mouse TCRs found tumor regression in patients with melanoma. 
However, patients enrolled in the clinical trial also exhibited toxicities in tissue with 
normal melanocytes (Johnson et al., 2009). Clinical trials targeting the CTA NY-
ESO-1 had objective responses (OR) in 4 out of 6 patients with synovial cell 
sarcoma and 5 out of 11 patients with melanoma (Robbins et al., 2011). The most 
successful application of targeting a TAA comes from CAR T cells re-directed to 
the B cell antigen CD19 (Grupp et al., 2013; Porter et al., 2011). A single infusion 
of CD19 CAR T cells led to complete remission in 90% of patients with relapsed or 
refractory acute lymphoblastic leukemia (ALL). The most common severe adverse 
event (SAE) in early clinical trials of CD19 CAR T cells was cytokine release 
syndrome, which is mitigated by anti-IL-6R or anti-IL-6 monoclonal antibody 
therapy (Grupp et al., 2013). Despite these astonishing clinical outcomes, the 
therapy is not without its trade offs, as all responding patients experience B cell 
aplasia, which can be remedied with antibody replacement therapy (Maude et al., 
2014). Hematological malignancies are proof-of-concept that CAR T cell treatment 
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can lead to lasting clinical results; however, the lion’s share of human tumor burden 
lies in solid tumors (Siegel, Miller, & Jemal, 2019). 
Solid tumors present a special problem in that tumor antigen expression 
can overlap with vital organs and thus needs to be approached with extra caution. 
One report using an affinity-tuned scFv to either EGFR or HER2 antigen 
desensitized CAR T cells to normal cells that express these TAAs and helped to 
improve selectively for tumors that overexpress these TAAs (Liu et al., 2015). 
Another study found that using a 4-1BB co-stimulatory domain on a PSCA CAR, 
instead of a CD28 domain, mitigated off-target toxicities in a xenograft model 
(Priceman et al., 2018). These design considerations could be implemented to 
improve the safety profile of CAR T cells re-directed towards TAAs but the safer 
alternative is re-directing T cells to target TSAs. 
TSAs are expressed exclusively on tumor cells and can be immunogenic 
because they mark a clear destinction from normal, unmutated self-antigens. TSAs 
that are shared among different patient tumors are rare and desirable targets. A 
prime example is the TSA EGFR variant III (EGFRvIII). EGFRvIII is a splice variant 
of the receptor tyrosine kinase EGFR that is often found amplified in many 
malignancies. Genetically, the splice variant joins exons 1 and 8 in a novel 
molecule that results in constitutive activation of EGFRvIII. Consequently, the 
fusion between exons 1 and 8 of EGFR also forms an immunogenic epitope that 
can be detected by the immune system (Gan, Cvrljevic, & Johns, 2013; Sampson 
et al., 2014). On the basis of this finding, CAR T cells and vaccine approaches 
have been developed to target EGFRvIII (Johnson et al., 2015; Sampson et al., 
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2009). A more encompassing but highly personalized approach to identifying TSA 
is to scan the tumor exome for potential neo-antigens. This approach was first 
reported in a case involving a patient with metastatic cholangiocarinoma. A CD4+ 
T cell clone reactive to a mutation in ERBB2IP was identified within the patient’s 
tumor. Adoptive transfer of ex vivo expanded, ERBB2IP-specific reactive T cells 
mediated regression and tumor control (Tran et al., 2014). This approach was 
further advanced through the targeting of mutations in common oncogenes, as in 
the report where a T cell clone reactive to KRASG12D was isolated and used to treat 
patients with KRASG12D-driven tumors (Tran et al., 2015; Tran et al., 2016). Taken 
together, the advent of technology that can pan for TSAs and the facile use of 
gene-transfer of TCRs or CARs in T cells will help accelerate the development of 
new ACT therapies that target TSAs. 
While the dichotomy of TAAs and TSAs remains an important consideration 
in target selection, another class of TAAs blurs this distinction. Viruses and their 
gene products are highly immunogenic due to their foreign nature and are readily 
detected by the host immune system. The capacity of some viruses to transform 
an infected cell can present a platform by which T cells can be re-directed to kill 
tumor cells. Ex vivo expanded T cells specific to Epstein-Barr virus (EBV) were 
adoptively transferred to patients with various EBV-associated malignancies. 
Complete responses were observed in 4 out of 7 patients, demonstrating the 




Viruses and cancer: 
Viruses play a special role in the history and study of cancer research. 
Through investigation of the cause of a transmissible form of sarcoma in chickens, 
the nature of oncogenes in humans was ultimately illuminated. The Rous sarcoma 
virus (RSV) was observed to reproducibly transform infected chicken cells in vitro 
and served as tool to understand the genetics of cancer (Bister, 2015). Hidden 
within the viral genome of RSV, lies the vSRC (viral Sarcoma) gene, which was 
found to be the genetic driver of transformation in infected chicken cells (Duesberg 
& Vogt, 1970; L. H. Wang, Duesberg, Kawai, & Hanafusa, 1976). This discovery, 
in itself, might seem trivial to a researcher outside the field of tumor virology; 
however, the true implications of this discovery only became apparent when a 
larger form of the vSRC gene was also found in the host cell genome (Stehelin, 
Varmus, Bishop, & Vogt, 1976). What was true for the chicken was also true of 
man, as the human genome also carried a SRC homologue. The genetic 
underpinnings of cellular transformation were not entirely foreign entities but rather 
endogenously found scattered throughout the human genome. Proto-oncogenes, 
as these genes were later named, are the genes that can drive cellular 
transformation when their function is altered via mutation (Vogt, 2012). Oncogenes 
also underscore an immunotherapy dilemma: if tumors can arise from 
spontaneous mutations in self-antigens, how can they be safely targeted with re-
directed T cells? Categorically, mutated self-antigens occupy an immunological 
grey area that renders them difficult to target due to immunological tolerance as 
outlined in the previous section. In contrast, oncogenic viruses and their gene 
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products do not share this feature in that viral gene products are readily detected 
by the immune system as foreign antigens. 
Given the history of viruses and cancer, it is not surprising that oncogenic 
viruses account for 15-20% of all human malignancies worldwide (Mesri, Feitelson, 
& Munger, 2014; Mittal et al., 2014). Oncoviruses, such as EBV, human 
papillomavirus (HPV), and Kaposi’s sarcoma-associated herpesvirus (KHSV), 
have been directly linked to cell transformation via a myriad of viral gene products 
that inactivate host tumor suppressor genes or mimic the function of oncogenes 
(reviewed in (Krump & You, 2018). Viewed through the lens of cancer 
immunotherapy, targeting foreign antigens expressed by oncogenic viruses 
presents an attractive platform to treat virus-associated malignancies. GBM does 
not have an association with a causally linked oncogenic virus; however, reports 
have demonstrated that human cytomegalovirus (HCMV) resides within GBM 
tumor cells. HCMV has reportedly been found in many cancer types, including low- 
and high-grade gliomas, EBV-negative Hodgkin's disease, prostate and colorectal 
cancers (C. S. Cobbs et al., 2002; Harkins et al., 2002; G. Huang et al., 2002; 
Libard et al., 2014; Scheurer, Bondy, Aldape, Albrecht, & El-Zein, 2008). Unlike 
oncogenic viruses with a known mechanism of transformation, HCMV has not 
been linked to cancer transformation, instead it has been designated as an onco-
modulatory virus (Dziurzynski et al., 2012). Onco-modulatory viruses may confer 
a tumorigenic phenotype unto an infected cell via the function of viral gene 
products. The high association of HCMV with GBM and reports of its presence in 
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other malignancies has captured the attention of clinicians seeking to target this 
virus for cancer treatment. 
 
Natural History and the immune response to HCMV: 
HCMV is a ubiquitous DNA virus with population infection rates that range 
from 50-80% based on different factors (Roddie & Peggs, 2017). Acute infection 
is often asymptomatic and results in a life-long chronic latent infection in people 
exposed to the virus. Fulminant HCMV reactivation develops in the context of 
immune suppression or in individuals with a compromised immune system. Of 
particular note are patients that have undergone an organ transplant or allogeneic 
stem cell transplant are at high risk to develop HCMV reactivation (Gandhi & 
Khanna, 2004). It is the window of immune reconstitution after HSCT that the virus 
can come out of dormancy from the reservoir cells. Typically, the main viral 
reservoir for HCMV is considered to the be CD34+ cells of the HPSC compartment 
(Sinclair & Sissons, 2006). It is in these cells that the virus can express a latent 
gene expression profile and avoid cellular immune responses. Monocytes derived 
from infected CD34+ progenitors can initiate lytic infection when these cells 
undergo differentiation in peripheral tissues (Sissons, Bain, & Wills, 2002). This 
shedding into the periphery is subverted and kept under control by a strong cellular 
immune response and is sufficient to control and prevent HCMV reactivation. It is 
estimated that approximately 10% of the memory CD4+ and CD8+ T cell 
compartment is devoted to responding to HCMV infection (Sylwester et al., 2005). 
The importance of a cellular immune response is also reflected in clinical studies 
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that performed adoptive transfer of HCMV-specific T cell clones to reconstitute 
anti-HCMV immunity in patients after a bone marrow transplantation (Riddell et al., 
1992; Walter et al., 1995). However, if a cellular immune response is not available 
reactivation can lead to clinical complications. The high morbidity associated with 
HCMV has prompted the development of vaccines targeting immunodominant viral 
antigens. To date, no prophylactic vaccine has been approved for HCMV. This 
could be attributed, in part, to the highly adept ability of HCMV to evade and 
subvert the host immune response. HCMV produces a viral homolog of IL-10, 
which dampens immune responses and down regulates HLA presentation of viral 
peptides. Moreover, NK cells are evaded via a viral protein that mimics the function 
of HLA (Michaelis, Doerr, & Cinatl, 2009). Taken together, while the immune 
system is able to mount a robust immune response and suppress reactivation, but 
it is not sufficient to rid a host of the HCMV reservoir. Vaccinations based on HCMV 
antigens result in potent humoral immune responses and the viral antigen 
glycoprotein B (gB) has been identified as a vaccine candidate (Lilja & Mason, 
2012). The humoral immune responses to gB are not effective at preventing 
infection and the robust response to the immunodominant epitope produces non-
neutralizing antibodies, which outcompete neutralizing antibodies (Speckner, 
Glykofrydes, Ohlin, & Mach, 1999). The natural history of HCMV infections 
underscore why the virus is prevalent among humans and in addition why it is able 




HCMV and GBM: 
The association between HCMV and GBM was first reported in 2002. 
Charles Cobbs, a neurosurgeon at University of Alabama was interested in 
discovering the underlying cause of inflammation found in GBM tumors. The report 
demonstrated the presence of CMV antigens and nucleic acids in GBM tumors but 
not the surrounding normal brain tissue (C. S. Cobbs et al., 2002). Following the 
first report, a group at Duke University demonstrated the presence of the virus in 
up to 90% of GBM tumor samples collected at their medical center (Mitchell et al., 
2008). Despite initial reports demonstrating positive associations between GBM 
and CMV, the reproducibility of these findings has been called into question as 
other groups have failed to detect HCMV in their GBM samples (Davis & van der 
Merwe, 2006; Garcia-Martinez et al., 2017; Priel, Wohl, Teperberg, Nass, & 
Cohen, 2015). As Cobbs argues in a response letter, the negative results ultimately 
falls upon the sensitivity and optimization of the methods used to detect the virus 
(Cobbs, 2014). 
Given the propensity of HCMV to be confined within GBM tumor and not the 
surrounding normal brain tissue, clinicians have set out to leverage the tumor-
specific localization as a platform for GBM immunotherapy. Early evidence of the 
ability to detect CMV in GBM tumors came from a dendritic cell vaccine pulsed 
with autologous GBM tumor lysate. After one vaccination, a dramatic increase of 
T cells recognizing the immunodominant epitope of CMV, pp65, was observed in 
one patient (Prins, Cloughesy, & Liau, 2008). Other groups set out to determine if 
patient-derived HCMV-specific T cells expanded ex vivo can detect autologous 
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GBM tumors in vitro. The results of this study found that specific T cells were able 
to sense and kill virus-infected GBM cells (Nair et al., 2014). These reports 
demonstrate that T cells are sensitive enough to detect CMV antigens on tumor 
cells and are sufficient to trigger T cell killing of the infected tumor cell. 
Building on these clinical studies is a series of clinical trials using dendritic 
cell vaccines pulsed with CMV antigen pp65 for GBM immunotherapy. Initial 
reports used dendritic cells pulsed with pp65 mRNA and tetanus toxoid adjuvant. 
The mechanism underlying a robust immune response to the tumor was 
dependent on CCL3 (Mitchell et al., 2015). Follow-up studies have used variants 
of dendritic cells pulsed with pp65 and high intensity chemotherapy with varying 
levels of success (Batich et al., 2017). One study combined both adoptive cell 
transfer of HCMV-specific T cells in conjunction with dendritic cells pulsed with 
pp65. The result was restoration of polyfunctionality of adoptively transferred T cell 
uncovering a potential new mechanism of dendritic cells to rejuvenate exhausted 
T cells (Reap et al., 2018). Collectively these clinical studies demonstrate the 
feasibility and potential benefit of targeting CMV in GBM. 
 
 
Targeting of GBM using anti-CMV CAR: 
Missing from the clinical studies outlined in the previous section is an 
immunotherapy approach using CAR T cells re-directed to CMV as a way to target 
GBM. Unlike TCR-mediated recognition of target via MHC, CAR T cells rely on 
surface expression of the target antigen to initiate killing. Given so, the viral 
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genome of CMV encodes a variety of surface proteins amenable to CAR 
recognition. The ideal CMV antigen would be 1) a surface-bound molecule, 2) 
highly conserved among clinical strains of CMV, and 3) abundantly expressed on 
the tumor cell. One HCMV antigen that meets these criteria is gB, which is an 
extracellular viral antigen involved in the process of membrane fusion between 
CMV envelope and host cells (Gardner & Tortorella, 2016). Given the role in viral 
dissemination and cell entry, gB was used as a vaccine antigen in clinical trials but 
has not resulted in protection from HCMV infection (reviewed in (Anderholm, 
Bierle, & Schleiss, 2016). Despite these set backs, the humoral immune response 
induced in response to gB has yielded valuable information about epitopes found 
on gB that can guide CAR design (Ohlin & Soderberg-Naucler, 2015). Humoral 
immune responses to HCMV often fail to neutralize the virus due to competition 
for the immunodominant epitope of gB (Speckner et al., 1999). Moreover, 
neutralizing antibodies bound to gB can be internalized and incorporated into the 
viral envelope. Paradoxically, Fc receptor engagement and engulfment of a 
neutralizing antibody bound to gB on the HCMV envelope enhances the spread of 
HCMV into immune cells that the virus would not normally infect (Manley et al., 
2011). Mechanisms of evading humoral immune responses directed against gB 
demonstrate the importance of maintaining a functional gB in the HCMV lifecycle 
(Gardner & Tortorella, 2016) Lastly, surface expression of gB has been reported 
in GBM (Mitchell et al., 2008; Ranganathan, Clark, Kuo, Salamat, & Kalejta, 2012). 
Investigators found that gB augments tumorigenicity of GBM via interaction of 
PDGFRa and gB (C. Cobbs et al., 2014). The association of PDGFRa with gB is 
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not surprising, given that the same group discovered that gB utilizes PDGFRa as 
an entry receptor into host cells (Soroceanu, Akhavan, & Cobbs, 2008). Taken 
together, the extracellular expression of HCMV gB on GBM tumors presents a 
target that is amenable to CAR recognition and has potential use for GBM 
immunotherapy. 
We set out to evaluate the anti-tumor activity of CAR T cells re-directed to 
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HCMV was initially reported to be found in GBM in 2002 (C. S. Cobbs et al., 
2002). Soon after the report was published, other labs reported not being able to 
replicate the initial reports (reviewed in (Rahman, Dastmalchi, Karachi, & Mitchell, 
2019). Detection of HCMV in GBM tissue is fraught with methodological and 
sample collection issues (C. Cobbs, 2014). Sensitive detection of the low levels of 
HCMV requires optimized protocols and high quality specimens (C. S. Cobbs, 
Matlaf, & Harkins, 2014).  
How HCMV contributes to GBM’s tumorgenicity/tumorigenesis has been a 
topic of consideration. Of interest are the host factors found within tumor cells and 
how they can contribute to HCMV infectivity. GBM is a highly heterogenous tumor 
and can be defined by molecular alterations and deletions found within the tumor. 
The four subtypes that emerged from molecular characterization of GBM are the 
classical, proneural, mesenchymal, and neural (Verhaak et al., 2010). 
Amplification of EGFR and PDGFRa in certain GBMs may render these tumors 
more susceptible to HCMV infection. The degree of HCMV infection could hold 
prognostic value for patients with GBM. GBM tumors for immunohistochemistry 
(IHC) stained for HCMV IE1-72 were stratified into low- and high-grade infection 
groups. Patients with tumors displaying a low-grade infection had longer survival 
(Rahbar et al., 2013), suggesting that HCMV may contribute to the pathogenesis 
of GBM. In this study, we set out to confirm the presence of HCMV in GBM sample 
collected at the Hospital of the University of Pennsylvania (HUP). Additionally, we 
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HCMV IE1-72 expression detected in primary GBM tumors 
 
The presence of HCMV antigens has been reported in a high percentage of GBM 
cases (C. S. Cobbs et al., 2002; Mitchell et al., 2008; Scheurer et al., 2008). In 
order to verify this association, we performed IHC on nine primary GBM samples 
acquired at HUP. Sensitive IHC detection of HCMV IE1-72 protein was optimized 
to detect low levels of HCMV antigen expression typically found in GBM (C. S. 
Cobbs et al., 2002; Mitchell et al., 2008; Scheurer et al., 2008). Seven out of nine 
(77%) primary GBM cases showed positive staining for HCMV IE1-72. A high 
degree of heterogeneous HCMV IE1-72 antigen expression was found within the 
tumor and among the cases screened. No immunoreactivity was found in sections 
where the primary antibody was excluded (Fig. 3.1). Given the high prevalence of 
HCMV in GBM samples acquired at the Hospital of the University of Pennsylvania 
(HUP) and the reported expression of other HCMV antigens in GBM (Rahman et 
al., 2019), HCMV became attractive as a target platform to re-direct T cells to GBM. 
 
CMV is preferentially found in the proneural subtype of GBM 
 
We next sought to confirm expression of CMV gene UL55 (glycoprotein B) in 40 
primary GBM tumor samples collected at the Hospital of the University of 
Pennsylvania. The 40 GBM samples were designated into one of the four GBM 
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molecular phenotypes (Pal et al., 2014; Verhaak et al., 2010) and were screened 
for gB expression using a sensitive nested RT-PCR (C. S. Cobbs et al., 2014). Of 
the 40 samples, 18 tested positive for gB expression (45%) confirming similar 
findings by other groups (Mitchell et al., 2008; Ranganathan et al., 2012) (Fig 3.2). 
Interestingly, we observed preferential expression of gB within the proneural 
subtype (8/8). We hypothesize that the enrichment of expression of gB within the 
proneural subtype correlates with the ability of this gB to ligate PDGFRa and 
induce mitogenic signaling (C. Cobbs et al., 2014; Soroceanu et al., 2008). Taken 
together, the high incidence of CMV antigens present in GBM samples and the 
confirmation of gB expression in primary tumors could be used as a platform to re-
direct T cells to GBM. 
 
Materials and methods 
Detection of HCMV antigens in primary GBM tumors 
Both detection of IE1-72 antigen on primary GBM FFPE sections using IHC and the 
sensitive RT-PCR detection of UL55 expression in cDNA generated from primary GBM 
followed the protocol outlined in C. S. Cobbs et al. (2014). PCR reactions were prepared 
in an AirClean 600 PCR workstation (AirClean Systems). Positive control reactions were 
prepared last and run on a separate PCR machine in a different room to avoid cross-
contamination. Human adult normal cerebral brain cortex cDNA were commercially 
obtained (BioChain). Primers used for amplification were as follows:  




gBRinternal 5’- GTAAACCACATCACCCGTGGA-3’. 
Microscopy 
Microscopy was performed using a Leica DFC7000 system. Bright field images 
were taken in regions representative of IE1-72 staining grade. Automatic contrast 
was applied to images. 
 
Discussion: 
The central questions of this chapter are: can we detect the virus in samples 
derived at HUP and how do host factors influence HCMV infectivity of GBM? 
Sensitive detection of HCMV in GBM FFPE sections revealed a high degree on 
HCMV infection in GBM samples acquired at HUP. The staining intensity of IE1-
72 varied among cases but HCMV can be detected with an optimized protocol. 
Given the high degree of optimization required to detect the HCMV, no protocol 
has been published for IHC detection of gB. It is important develop a baseline 
method of detecting HCMV by using IE1-72 staining before optimizing a gB 
staining protocol. This would reduce the chances of a false negative result by first 
detecting IE1-72 and then staining for gB. Due to HCMV expression kinetics during 
lytic infection, gB is expressed approximately two days after lytic infection, while 
IE1-72 is expressed at all stages of lytic infection (Radsak et al., 1996).  
 The contribution of host factors in facilitating HCMV infectivity in GBM 
warrants additional experiments. HCMV utilizes host factors for cell entry; of note 
are the RTKs EGFR and PDGFRa that are often amplified in certain GBMs 
(Gardner & Tortorella, 2016). The results reported here suggest that gB expression 
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might be highest in proneural subsets of GBM but does not preclude the presence 
of the virus in the other GBM subtypes. High levels of gB expression in proneural 
GBMs make gB CAR T cells good candidate for patients with proneural GBMs. 
However, one must consider the limitations of the technology used to subtype 
GBMs. Small clusters of cells might influence the subtype a certain GBM is 
designated. Moreover, subtyping presents a snapshot of the tumor sample at the 
time of collection. As it has become evident, GBMs undergoes tumor evolution 
from initial diagnosis and recurrence (Q. Wang et al., 2017). The morphing of GBM 
from one subtype to another in response to treatment has also been reported. 
Clonal variation within a GBM selects for pre-existing resistant clones to dominate 
the tumor mass. Proneural GBMs often morph into radiotherapy- and 
chemotherapy-resistant mesenchymal GBMs (Segerman et al., 2016). Thus, 
subtyping of GBM with regard to HCMV may not be as useful as initially thought. 
Given these results, the question of what subtype might be enriched for HCMV 
should be modified to consider the effect of treatment on HCMV status. Does 
HCMV status change from initial diagnosis and at reoccurrence? If GBM subtype 
transitions occur, do the associated changes in the tumor and TME favor HCMV 
infection of GBM or dissemination of HCMV into the tumor site?  Mesenchymal 
GBMs found at reoccurrence are often found to be associated with an influx of 
macrophages, a known carrier of HCMV (Sinclair & Sissons, 2006; Q. Wang et al., 
2017). HCMV’s ability to infect different cell types within the TME brings up the 
question of which cells in the TME harbor the virus. This question has been partially 
answered by a report demonstrating that glioma cancer stem cells and glial cells 
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are enriched for the virus (Dziurzynski et al., 2011). Additional experiments 
determining the in situ localization of HCMV within specific cell types could 
illuminate potential targets for gB CARs within the TME.  
 Experiments to address some of the questions listed above would require 
a set of matched GBMs at initial diagnosis and again at reoccurrence. These 
matched samples can be IHC stained for IE1-72 and pp65 to determine if HCMV 
infection in GBM tumor tissue spreads or is reduced after treatment. Markers for 
glioma stem cells can be used in conjunction with HCMV IE1-72 to determine co-
localization of virus and glioma cancer stem cells (gCSCs) or tumor-associated 
macrophages (TAMs). Additionally, a validation set of subtyped GBMs can confirm 
the incidental finding that proneural GBMs are enriched for gB expression using a 
nested PCR reaction for gB.  













Figure 2.1. Immunohistochemistry (IHC) for CMV antigen IE1-72 on primary glioblastoma 
tumors. IHC was performed on 9 formalin fixed paraffin-embedded (FFPE) glioblastoma 
samples collected at the University of Pennsylvania hospital. 9 primary GBM samples 
were graded on a 0-4 scale for IE1-72 positivity, with grade 0 indicating IE1-72 negative, 
and grades 1-4 as positive with increasing staining intensity. Shown are representative 
images for each staining grade. Magnification 200x. Negative control sections consisted 







Figure 2.2. CMV antigen gB is expressed in primary GBM tumor tumors. Complimentary 
DNA (cDNA) from 40 primary GBM tumor samples were screened for expression of CMV 
gene UL55 (glycoprotein B) as a marker of CMV presence in the tumor samples. The 
results of a sensitive nested reverse transcriptase polymerase chain reaction (RT-PCR) 
reaction for expression of CMV gene UL55 are depicted. The distribution of molecular 
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Glioblastoma multiforme (GBM) is the most common and deadliest adult primary brain 
tumor. Immunotherapeutic approaches using chimeric antigen receptor (CAR) T cells 
have shown limited efficacy against GBM due in part to heterogeneous target antigen 
expression. Human cytomegalovirus (HCMV) can be detected in up to 90% of GBM 
samples but not in the surrounding normal brain tissue. We hypothesized that the 
presence of HCMV within GBM presents a novel approach by which T cells can be 
redirected to GBM. We generated a CAR optimized to recognize the HCMV surface 
antigen glycoprotein B (gB). In vitro testing of the anti-gB CAR T cells revealed specific 
activity against glioma cells expressing gB and HCMV-infected cells. Importantly, gB CAR 
T cells were able to recognize ex vivo cultured primary GBM tumors. Finally, gB CAR T 
cells exhibited anti-tumor activity in vivo against GBM tumors in a xenograft mouse model. 
These results suggest that CAR T cells may be effective in recognizing HCMV antigens 
found within GBM. Taken together, the results of this study show the feasibility of using 















 Chimeric antigen receptors (CAR) are synthetic gene constructs that most 
commonly combine the specificity of monoclonal antibodies with the signaling domains of 
co-stimulatory molecules and TCR zeta chains. CARs can be used to redirect T cells to 
surface antigens by changing the specificity of the recognition domain. This approach has 
been used successfully in the use of CAR T cells to treat hematological malignancies 
leading to the first clinical approval of a CAR T cell therapy for acute lymphoblastic 
leukemia (Maude et al., 2014). However, in the realm of solid tumors CAR T cells have 
shown limited efficacy, in part due to the heterogeneous expression of target antigen and 
the associated safety profile of targeting tumor-associated antigens. Target antigens on 
solid tumors offer a special problem in that often tumor-associated antigens are found on 
normal tissue of vital organs or have heterogeneous expression on the tumor cells. This 
problem is particularly challenging in the development of CAR T cell therapies directed 
against glioblastoma (GBM).  
GBM is an intractable tumor with a grim prognosis. Median life expectancy with 
current standard of care is approximately 15 months. Current standard of care consists of 
surgical resection and concomitant radiation and chemotherapy (Stupp et al., 2005; Wen 
& Kesari, 2008). The current modalities used to treat GBM are imprecise and often do not 
prevent tumor recurrence. Adoptive transfer of gene-engineered T cells offers greater 
specificity for tumors than conventional therapies but has had limited success in clinical 
trials against GBM. A clinical trial using CAR T cells re-directed to EGFRvIII led to a 
reduction of EGFRvIII-expressing tumor cells but did not cause significant tumor reduction, 
potentially due to antigenic heterogeneity (O'Rourke et al., 2017). CAR T cells targeting 
IL13Rα2 in a phase I clinical trial showed tumor regression, a 9-month remission, and 
relapse with antigen-negative GBM in one patient (Brown et al., 2016). These studies 
highlight the challenges of targeting GBM, which displays significant heterogeneity in 
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antigen expression and the need to identify additional target antigens present within GBM 
(deCarvalho et al., 2018; Francis et al., 2014; Little et al., 2012).  
 Human cytomegalovirus (HCMV) is a tumor-associated antigen that has been 
detected in up to 90% of GBM cases (Mitchell et al., 2008). The mechanism of HCMV 
expression in GBM remains unknown but HCMV proteins have been reported to enhance 
tumorigenicity (Dziurzynski et al., 2012). HCMV antigen glycoprotein B (gB) has been 
shown to be expressed in primary GBM and contribute to GBM invasiveness in mouse 
models (C. Cobbs et al., 2014). gB is a highly conserved fusogenic protein found on the 
HCMV envelope known to assist HCMV in viral entry into host cells (Gardner & Tortorella, 
2016). During HCMV lytic infection, surface expressed gB aids HCMV in cell-to-cell spread 
(Isaacson & Compton, 2009). Moreover, gB is one of the most abundant extracellular 
HCMV antigens and thus potentially available to CAR T cell recognition (Varnum et al., 
2004). Evidence for targeting HCMV proteins as a tumor-associated antigen in GBM 
comes from clinical trials using dendritic cell vaccines. In one clinical trial, autologous 
dendritic cells pulsed with GBM tumor lysate led to the expansion of HCMV-specific T cells 
in one patient (Prins et al., 2008). Another study used HCMV antigen pp65 mRNA pulsed 
into autologous dendritic cells with tetanus toxoid adjuvant, leading to prolonged survival 
in patients with GBM (Mitchell et al., 2015). Lastly, a study conducted by Nair et al. 
demonstrated that HCMV-specific T cells expanded from patients with GBM were able to 
recognize the patient’s autologous GBM, adding to the rationale to target HCMV in GBM 
(Nair et al., 2014).  
The high prevalence of HCMV in GBM tumors suggests that T cells could be re-
directed to recognize and kill HCMV-infected glioma cells. HCMV is a foreign virus with 
high immunogenicity allowing for generation of strong immunological responses to its 
antigens and potentially to GBM. We set out to determine the feasibility of generating an 
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Epitopes of HCMV gB 
The human donor derived mAb ITC52 was isolated from immortalized B cells and 
was determined to be specific for gB antigen domain 1 (AD-1). Precise epitope 
mapping of ITC52 revealed recognition of a discontinuous epitope in AD-1 
corresponding to two residues 570-579 and 606-619 of HCMV gB (Ohlin, 
Sundqvist, Mach, Wahren, & Borrebaeck, 1993). Moreover, alignment of the amino 
acid sequences of 60 different HCMV strains shows a high degree of amino acid 
conversation among strains in AD-1 (Figure 3.1). A common substitution mutation 
found in gB AD-1 corresponding to residue F611L does not prevent recognition of 
both variants of gB (Speckner et al., 1999). These data suggest that a gB-specific 
CAR bearing the ITC52 scFv would have near universal recognition of all HCMV 
strain specific gB variants. 
 
Design and optimization of anti-HCMV gB CAR T cells  
 
Based on the observed expression of CMV antigen IE1-72 within primary GBM FFPE 
samples (Fig.2.1) we next set out to design a chimeric antigen receptor (CAR) that can 
detect membrane-bound HCMV glycoprotein B (gB) antigen reported to be expressed in 
GBM (C. Cobbs et al., 2014). We generated a second-generation CAR that incorporated 
the CD137 (4-1BB) co-stimulatory domain with TCR zeta signaling (Milone et al., 2009) 
(Fig. 3.2 A). The scFv used was derived from the variable domains of the human 
monoclonal antibody ITC52, which recognizes the membrane distal epitope AD-1 found 
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on gB (Burke & Heldwein, 2015; Heldwein et al., 2006; Schoppel et al., 1996). The scFv 
was generated in two orientations with the variable heavy and light chains connected via 
a 3x(GGGGS) spacer domain onto a CD8a hinge domain (Fig. 3.3 A). To determine the 
optimal scFv orientation, the CAR constructs were evaluated utilizing multiple 
immunoassays against the human glioma tumor cell line, U87, which was lentivirally 
transduced to stably express gB (Fig. 3.2 A). HCMV gB is not naturally expressed in U87 
and ectopic expression of the target antigen allows specificity determination of gB CAR 
constructs. Cytokine production, as determined by intracellular cytokine staining (ICCS) 
and flow cytometry, was higher in the T cells bearing the CAR with scFv orientation of light 
to heavy (L2H) as compared to T cells bearing the CAR with H2L scFv orientation (Fig. 
3.2 B). The L2H orientation also showed significantly greater cytolytic function by 51Cr-
release assay (Fig. 3.2 C).  
We further optimized the design of the anti-gB CAR by testing various hinge 
domains (Fig. 3.3 A). We hypothesized that there may be an optimal hinge length between 
the apical AD-1 epitope found on gB and our CAR expressing T cells as demonstrated 
previously in other CAR models (Hudecek et al., 2013; S. E. James et al., 2008). We 
generated three additional gB CAR constructs using the long IgG4 hinge, IgG4/2NQ 
mutant hinge, and a short 12 amino acid hinge derived from the dimerization core of the 
IgG4 Fc domain (Hudecek et al., 2015) (Fig.3.3 A). The four gB L2H CAR constructs were 
tested via ICCS for production of IFN-γ, TNF-α, IL-2, and CD107a. CAR T cells expressing 
the short 12aa hinge domain exhibited the highest levels of cytokine production and 
CD107a marker of degranulation, consistent with a report of CAR T cells targeting the 
apical epitopes of ROR1 using a short spacer domain (Fig. 3.3 B) (Hudecek et al., 2013). 
Interestingly, the cytolytic activity of the three CAR constructs differed from their cytokine 
production activity. CAR T cells bearing the mutated IgG4/2NQ domain displayed higher 
cytolytic activity in a 6-hour 51Cr release assay (Fig. 3.3 C). Based on the divergent in vitro 
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effector activities of the short (12aa) and long hinge (IgG4/2NQ) gB CARs we selected 
these two CAR constructs for further evaluation.  
The initial in vitro testing of our CAR constructs relied upon the transduced U87 
glioma cell line expressing artificially high levels of gB antigen (Fig.3.2 A). We set out to 
evaluate how gB CAR T cells respond to cells naturally infected with HCMV. gB expression 
during the course of infection undergoes a dynamic process, where antigen is initially 
trafficked to the surface of infected cells and then endocytosed to an intracellular viral 
envelopment compartment (Radsak et al., 1996). We tested the ability of anti-gB CAR T 
cells to respond to human foreskin fibroblasts (HFF) infected with HCMV. Expression of 
gB was monitored in HCMV-infected HFFs over the course of five days (Fig.3.4A). On day 
four post infection, gB CAR T cells were co-cultured with mock infected or infected HFF 
cells. gB CAR T cells were able to detect gB expressed on HCMV-infected HFF cells at 
levels comparable to positive control targets (Fig.3.4 B). Moreover, the pattern of 
recognition was similar to that previously observed in U87gB, with the short hinge gB 12aa 
CAR exhibiting the highest cytokine production. The ability of anti-HCMV CAR T cells to 
produce high levels of cytokines is a desirable feature for antiviral efficacy as another 
group has shown that TNF-α and INF-γ can inhibit HCMV replication in infected HFF cells 
(Proff, Brey, Ensser, Holter, & Lehner, 2018).  
 
gB CAR T cells recognize cognate antigen on some primary GBM tumors  
 
It is important to demonstrate that the gB CAR T cells can recognize the natural level of 
gB antigen expression found in primary GBM tumors. Low levels of target antigen 
expression on tumor cells could hinder the ability of CAR T cells to recognize and kill 
antigen-positive tumor cells (Walker et al., 2017). Previous studies using autologous 
HCMV-specific T cells co-cultured with the patient’s own tumor revealed the ability of T 
cells to sense endogenous levels of HCMV antigen within GBM tumors, presumably by 
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the endogenous CMV-specific TCR (Nair et al., 2014). However, despite demonstrating 
gB expression within GBM, levels of target antigen may be below the level of detection for 
CAR T cells (C. Cobbs et al., 2014; Dziurzynski et al., 2011; Mitchell et al., 2008). To test 
the ability of gB CAR T cells to recognize their cognate antigen on primary GBM tumors, 
we cultured short-term newly resected GBM tumors as targets in a 51Cr release assay. To 
promote retention of HCMV within primary GBM tumors, the cells were cultured in glioma-
stem cell promoting conditions (Fiallos et al., 2014). Glioma cell line U87 and U87gB were 
used as negative and positive control targets, respectively, to monitor CAR T cell activity 
(Fig.3.5A). One of the three primary tumors tested, tumor sample GBM-8017, was killed 
at low effector-to-target ratios when co-cultured with gB CAR T cells and not with negative 
control CD19 CAR T cells or untransduced T cells, excluding an allogeneic effect (Fig. 
3.5B). The other two primary GBM cells were not specifically lysed by gB CAR T cells. In 
contrast, the EGFR CAR T cells specifically killed the two GBM explants that were not 
lysed by the gB CAR T cells. We later confirmed expression of UL55 (gB) in GBM8017 via 
RT-PCR. These data support the hypothesis that gB CAR T cells are sensitive enough to 
detect extracellular expression of gB in some tumors at levels of natural HCMV infection 
within primary GBM tumor cells.  
 
gB CAR T cells delay GBM tumor growth in vivo  
 
Based on the observed anti-tumor activity of the gB CAR T cells in vitro we next sought to 
evaluate the impact of gB CAR T cell on tumor growth in vivo. High levels of in vitro activity 
could compromise the in vivo function of CAR T cells via induction of activation induced 
cell death (Kunkele et al., 2015). We tested the short (12aa) and long hinge (IgG4/2NQ) 
gB CAR constructs in an established human tumor xenograft model using NSG mice 
bearing subcutaneous tumors expressing gB (U87gB). Five days after tumor injection, a 
single injection of 5x106 CAR+ T cells was administered via tail vein (Fig.3.6A). All mice 
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treated with CAR T cells demonstrated tumor engraftment and progression. However, a 
significant reduction in tumor growth was observed in mice treated with either anti-gB CAR 
T cell as compared to negative control CD19 CAR T cell treated mice (Fig.3.6B,D). All 
mice treated with control CD19 CAR T cells succumbed to their tumor by day 30, while 
the gB CAR treated mice had a significant survival advantage (Fig. 3.6C). Surprisingly, 
despite both short and long versions of the gB CAR T cells displaying different in vitro 
activity, mice in both gB CAR T cell treated groups had a similar delay in tumor growth 
and a gain in survival in vivo (Fig.3.5C).  
 
CAR T cells recognize endogenous levels of HCMV gB expression in primary GBM 
tumor explants 
 
Having tested our anti-gB CAR T cells in vivo in a high antigen expressing pre-clinical 
model, we next evaluated the anti-tumor effect of gB CAR T cells in a low antigen 
expressing model. We screened human GBM explants for HCMV expression and found 
expression of target antigen gB in the human glioma explant D270. Despite being able to 
detect expression of gB in this cell line at the mRNA level, gB levels were below the level 
of antibody detection by flow cytometry (Fig 3.7A). Using a secondary marker for HCMV, 
we detected the expression of HCMV IE1-72 using a sensitive IHC protocol (Fig.3.7B). 
Surprisingly, low level gB expression was sufficient to induce potent and specific killing of 
D270 tumor cells when co-cultured with gB CAR T cells in 51Cr-release assays (Fig.3.7C). 
D270 cells have been shown previously to express EGFRvIII, and EGFRvIII CAR T cells 
were also effective. We next sought to evaluate the antitumor function of gB CAR T cells 
against D270 in a subcutaneous murine tumor model. We reasoned that D270 would be 
a realistic surrogate to evaluate the antitumor function of gB CAR T cells expressing 
natural levels of HCMV gB expressed in primary GBM tumors. Tumor bearing mice were 
treated with two doses of 5x106 CAR+ T cells, at day 3 and day 10 (Fig.3.8A). Mice treated 
with negative control CD19-specific CAR T cells demonstrated tumor growth comparable 
	 47	
to PBS treated mice (Fig.3.8B). In contrast, gB CAR T cell treated mice had significantly 
reduced tumor growth (Fig.3.8B). Interestingly, a small subset of gB CAR T cell treated 
mice controlled their tumors and displayed stable disease (Fig.3.8C). Taken together, anti-
gB CAR T cells lyse tumor cells expressing low levels of gB on the cell surface and have 
significant antitumor efficacy in vivo.  
 
 
Materials and Methods 
 
Cell lines and cell culture 
 
The human glioma cell lines U87 and U87-EGFRvIII were grown under conditions reported 
in Johnson et al. (2015). The U87-EGFRvIII parental cell line was lentivirally transduced 
to express HCMV gene UL55 (gB) and single cell cloned in flat-bottom 96-well plates. 
Human glioma xenograft explant D270 was provided by Darell Bigner (Duke University, 
Durham, NC). All glioma cell lines were grown in Improved MEM Zinc Option (Gibco) 
supplemented with 10% fetal calf serum (Seradigm), 1% penicillin and streptomycin 
(Gibco), 1% L-Glutamax (Gibco), 1% Sodium Pyruvate (Gibco), and HEPES buffer 
(20mM) (Gibco). Primary GBM tumors and cell lines were grown as described in 
(Roccograndi et al., 2017). GBM tissue was collected with informed patient consent, under 
a protocol approved by the University of Pennsylvania’s IRB. All samples were de-
identified before processing. Human foreskin fibroblasts (HFF) were mock infected or 
infected with TOWNE strain HCMV virus at a MOI of 5 to ensure close to 100% infection 
of target cells. Human glioma cell line U87 and U87gB was authenticated by the University 
of Arizona to confirm identify. D270 and primary HFF cells were screened to rule out cross 
contamination with other tumor cell lines. All cell lines used were tested and confirmed to 





Generation of CAR constructs  
 
Anti-gB CARs were generated from a pTRPE 5E5-CD8a-BBz and pTRPE 5E5-IgG4-BBz 
construct (Posey et al., 2016). These constructs were digested overnight using BspEI and 
BamHI restriction enzymes and gel extracted. Amino acid sequences of ITC52 scFv were 
found on GenBank accession	L26537 and L26538. Anti-gB single chain variable fragment 
(scFvs) were codon optimized for human expression and synthesized (Geneart, gBlock 
IDT) to contain the BspEI and BamHI restriction sites. Digested product was then ligated 
into pTRPE 5E5-CD8a-BBz and pTRPE 5E5-IgG4-BBz. Ligation products were 
transformed using Stbl3 chemically competent cells to prevent recombination of lentiviral 
vector. Hinge domains for IgG4/2NQ hinge were generated using site-directed 
mutagenesis using primers listed in Hudecek et al. (2015). The mutated hinge domain was 
then swapped into parental pTRPE ITC52 L2H IgG4 BBz digested with EcoRV and SalI 
restriction enzymes. 12aa hinge domain was made using oligonucleotides containing 
BamHI and EcoRV for amplification from pTRPE ITC52 L2H IgG4/2NQ BBz using the 
following primers: 1) 5’-GGATCCGAAATCGTTCTGACCCAG-3’, 2).5’-
GATATCAGGGCAAGGG-3’. The truncated hinge was then ligated into digested pTRPE 
backbone containing pTRPE ITC52 L2H. Generation of CD19 CAR was previously 
described in (Milone et al., 2009), EGFR CAR in (Wing et al., 2018), and EGFRvIII CAR 
in (Johnson et al., 2015), respectively.  
 
Transduction of T cells and expansion 
 
Normal donor leukocytes were isolated from leukapheresis product from de-identified 
normal donors by the Human Immunology Core of the University of Pennsylvania. T cells 
were stimulated with CD3/CD28 Dynabeads Human T-Activator (Life technologies) at a 
bead-to-cell ratio of 3:1. T cells were cultured in R10 media (RPMI 1640 medium 
supplemented with 10% fetal calf serum (Seradigm), 1% penicillin and streptomycin, 1% 
	 49	
L-Glutamax and HEPES buffer (20mM) (Gibco). IL-2 was added to the culture media at a 
final concentration of 30U/ml. Growth and expansion of the stimulated T cells was 
monitored using a Coulter Multisizer measuring cell density and mean lymphocytic volume 
and cells were frozen when T cells were rested (mean volumes of 300-330 fL).  
 
Intracellular cytokine analysis 
 
CAR T cells and untransduced T cells were cultured with target cells at an effector-to-
target ratio of 1:1. % CAR T cells were normalized to lowest percent transduction using 
untransduced cells. Effector T cells and tumor target cells were counted and resuspended 
at a density of 2x106/mL and seeded into a round bottom 96-well plate in 100µL. Co-
culture R10 media contained Golgi-stop and Golgi-plug (both BD Bioscience). Staining 
and processing of co-culture T cells was done as described in Johnson et al. (2015). Cells 




T cell killing was determined using standard 51Cr release assay. 51Cr release assay used 
targets that were labeled for up to two hours at 37°C with 50μCI of radioactive 51Cr. 
Labeled cells were washed twice in 10mL of non-phenol red culture media supplemented 
with 5% FBS and resuspended at a 1x105 cells/mL. One hundred microliters of labeled 
target cells were added to round bottom 96-well plate. Effector T cells were added to target 
cells in 100µL at different effector-to-target ratios. Absolute T cell count was normalized 
across all effector groups with the addition of untransduced T cells. The co-culture was 
run for up to 6-hours at 37°C. Thirty-five microliters of the supernatant was collected and 
transferred onto the filter of LumaPlate. The transferred supernatant was dried overnight 
on filter paper. Cytolytic activity of effector T cells was measured using a beta-emissions 
liquid scintillation counter (Perkin Elmer). Percent specific lysis was determined using the 
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following calculation: (sample counts-spontaneous counts)/(maximum counts-
spontaneous counts) x100.  
 
Murine Models  
NOD SCID gamma delta (NSG) mice were purchased from approved vendors (Jackson 
labs) and housed in a contained area. All mouse experiments adhered to Institutional 
Animal Care and Use Committee (IACUC) of the University of Pennsylvania. In the 
U87gB-EGFRvIII model, we followed the protocol established in Johnson et al. (2015). 
Tumor growth was evaluated via caliper measurement at regular intervals. Endpoint was 
determined by a tumor measuring 2cm in any dimension (length, width, height), loss of 
15% body weight, or inability to ambulate. In the D270 subcutaneous model, NSG mice 
were inoculated with 4x105 D270 cells in the mouse flank. Three days after tumor 
engraftment, mice were treated with CAR T cells at a dose of 5x106 CAR+ T cells per dose 
via tail-vein injection and again at day 10 after tumor injection. Absolute T cell count was 
matched for all groups with untransduced T cells.  
 
Statistical Methods 
Data is reported as means ± SD or SEM or as stated in figure legends. Statistical 
significance was determined using a standard two-way ANOVA for in vitro assays. 
Survival advantage for in vivo tumor challenges was determined using log-rank Mantel-
Cox. P values of less than 0.05 were considered statistically significant. All statistical 







The primary objective of this study was to determine if HCMV antigen gB could serve as 
a viable tumor-associated antigen for CAR T cells. The high prevalence of the virus in 
GBM samples make HCMV an attractive TAA (C. S. Cobbs et al., 2002; Mitchell et al., 
2008). The ability of CAR T cells to recognize their cognate antigen in an HLA-independent 
manner allows for a potentially broad clinical application of anti-HCMV CAR T cell therapy 
for most cases of GBM. gB is one of many potential HCMV-associated targets that been 
reported to be expressed within GBM that can be used to redirect T cells via CAR or TCR 
gene transfer (reviewed in (Rahman et al., 2019)). Moreover, HCMV antigens are readily 
recognized by the immune system due to their foreign nature and could increase the 
likelihood of inducing epitope spreading, which could benefit patients with GBM (Terrazzini 
& Kern, 2014).  
CAR T cells re-directed to gB have been previously reported (Full et al., 2010; Proff 
et al., 2018); the gB CARs in those reports were used to study the effects of retargeted T 
cells on acute infection with HCMV. However, to our knowledge the present work is the 
first report demonstrating that gB CAR T cells have promise as a therapeutic for GBM. 
Optimization of our anti-gB CAR underwent two phases, determination of the most 
sensitive orientation of the variable heavy and light fragments and selection of a hinge 
domain that allows more effective CAR T cell interaction with its cognate epitope. The 
epitope of ITC52 has been mapped to a membrane distal location atop of the gB trimer 
(Burke & Heldwein, 2015; Heldwein et al., 2006). Other groups have found that the avidity 
of the scFv and the location of the epitope on the cognate antigen has an effect on the 
efficacy of the CAR (Hudecek et al., 2013; S. E. James et al., 2008). These findings were 
consistent with our results in that the short, truncated hinge (gB 12aa) had the highest 
cytokine production.  
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Our results demonstrated in vivo antitumor efficacy of gB CAR T cells in two 
aggressive tumor models. Most strikingly, we observed antitumor efficacy in the D270 
tumor model. This was notable because of the low level of surface expression of gB, which 
was below the limit of detection by flow cytometry. CAR T cells, depending on the CAR 
construct and epitope that is targeted, have varying levels of sensitivity. For CD19, CAR 
T cells have been reported to require several hundred targets per tumor cell (Stone, 
Aggen, Schietinger, Schreiber, & Kranz, 2012), and more recently, a threshold for CAR 
recognition below 100 CD19 molecules per cell was reported (Nerreter et al., 2019). Thus, 
CAR T cells in optimal conditions can recognize targets at levels that are well below 
detection by flow cytometry. For potential application of CAR T for therapy of GBM, 
sensitive recognition of target will be important given the consensus that HCMV is 
expressed at low levels in GBM. 
 Targeting HCMV within GBM has shown some signs of promise in the clinic using 
TCR-based immunotherapies that target HCMV (Ahmed et al., 2017; Batich et al., 2017; 
Ghazi et al., 2012; Mitchell et al., 2015; Prins et al., 2008; Schuessler, Walker, & Khanna, 
2014). In a series of clinical studies using dendritic cell vaccines pulsed with pp65 in 
conjunction with adoptive transfer of HCMV-specific T cells, patients saw a restoration of 
poly-functionality in the adoptively transferred HCMV-specific T cells (Reap et al., 2018). 
An alternative approach to overcome the inherent barriers of low frequency or exhaustion 
of endogenous HCMV-reactive T cells is to use a gene-engineered approach to redirect 
polyclonal T cells to HCMV antigens. On this note, a report investigating tumor infiltrating 
T cells found HCMV-specific T cells to be present within GBM tumors; however, these 
cells displayed a tolerized and exhausted phenotype (Bahador et al., 2017). This study 
suggests that endogenous T cells primed via HCMV infection recognize HCMV antigen in 
the tumor but have a limited impact on tumor growth potentially due to the development 
of an exhausted phenotype. CAR T cells may fair better in the tumor microenvironments 
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but may be limited in their ability to clear all tumor due to heterogeneous expression of 
target antigens within GBM tumors (C. S. Cobbs et al., 2002; O'Rourke et al., 2017).  
 One limitation of our study is the inability to address the impact of inducing a recall 
response to HCMV in gB CAR T cell treated mice. Human cytomegalovirus is species-
specific and cannot infect other animal hosts; therefore, we were unable to interrogate the 
ability of endogenous polyclonal HCMV-specific T cells to be recalled and aid in the 
destruction of glioma cells infected with HCMV. A more pressing issue that gB CARs may 
face is the inability of a single scFv to recognize gB variants from clinical strains of HCMV 
due to mutations in the target antigen, potentially resulting in escape from detection by 
CAR T cells. Loss of recognition of the AD-1 epitope of the ITC52 monoclonal antibody 
has been reported. Small amino acid substitutions in the AD-1 epitope of gB lead to loss 
of neutralizing activity of AD-1 binding antibodies (Schoppel et al., 1996; Speckner et al., 
1999). How comparable mutations in clinical strains would compromise the ability of CAR 
T cells to recognize their target remains to be evaluated. Two modes of administering CAR 
T cell products to patients have been evaluated clinically. In a clinical trial using CAR T 
cells directed to EGFRvIII, patients were given CAR T cells in a single IV infusion. CAR T 
cells were able to traffic to the brain and kill EGRFvIII positive cells (O'Rourke et al., 2017). 
CAR T cells re-directed to IL13RA2 were given multiple doses intracranially over the 
course of week and demonstrated tumor regression in one case (Brown et al., 2016). Both 
modes of T cell administration allow T cells to perform anti-tumor function; however, it 
remains to be determined if one mode of delivery would have a greater clinical impact over 
another using the same CAR T cells administered through both routes.    
An alternative use of gB CAR T cells that we have developed is in the context of 
HCMV reactivation (Full et al., 2010; Proff et al., 2018). Adoptive cell transfer of viral-
specific T cells to control viral reactivation has been tested clinically with great success 
(Harris, Davila, Bollard, & Keller, 2019; Papadopoulou et al., 2014; Riddell et al., 1992). 
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These clinical trials demonstrate the feasibility of using cell transfer in controlling viral 
reactivation; however, to our knowledge and with the exception of HIV, no clinical trials 
have reported the use of CAR T cells as the modality of treatment for viral infection 
(Scholler et al., 2012). CAR T cells overcome a major limitation of ex-vivo expanded viral-
specific T cells by recognizing their cognate antigen in an MHC-independent fashion. 
Circumnavigating HLA-restriction allows for broad clinical application of virus-specific CAR 
T cells for patients with compromised or suppressed immune systems experiencing viral 
reactivation (Gandhi & Khanna, 2004; Jain et al., 2014).  
The use of CAR T cells simultaneously targeting multiple tumor antigens in GBM 
is a logical next step to overcome tumor heterogeneity. This approach is already being 
explored via the development of a trivalent CAR construct that simultaneously targets 
three tumor-associated antigens found in GBM (Bielamowicz et al., 2018). Additionally, 
CAR T cells redirected to IL13RA2 (Brown et al., 2016) and EGFRvIII (O'Rourke et al., 
2017) have proven to be safe and tolerated well by patients in clinical trials. Given the high 
prevalence of HCMV in GBM (C. S. Cobbs et al., 2002; Mitchell et al., 2008), the use of a 
gB CAR T cell in conjunction with other GBM CAR T cell targets could decrease tumor 











Figure 3.1. Sequence alignment of gB from clinical and lab-adapted strains of HCMV. 
Conserved residues among strains are highlighted in red; the dissentious epitope of 
mAb ITC52 is highlighted in blue; highlighted in yellow is L611F, the only residue 
substitution found in the epitope of ITC52.  AD169 and Towne represent lab-adapted 
strains. Toledo, VR1814, TR, Merlin, and TB40/E are representative clinical strains. 
HCMV gB sequences were exported from NCBI’s RefSeq or Uniport database. 







Figure 3.2. A. Expression of glycoprotein B (gB) on U87 human glioma cell transduced 
with gB antigen. The cell lines were immunostained with anti-gB monoclonal and 
analyzed via flowcytometry. Parental cell line U87 is shown in blue and U87gB shown in 
red. B. Expression of anti-gB CAR on transduced T cells. CAR T cells were 
immunostained with anti-human fab-biotin and PE-streptavidin secondary and analyzed 
via flow cytometry. CARs with different heavy and light chain orientation in the scFv were 
tested.  C. The function of gB CARs with L2H or H2L orientation was assessed by 
production of tumor necrosis factor-alpha (TNFα), interferon-gamma (IFNγ) via an 
intracellular cytokine-staining assay. Untransduced (UTD) control T cells and gB CAR 
expressing T cells from the same donor were co-cultured with human glioma cell line 
U87 or with U87 cells transduced with gB at an effector to target ratio of 1:1 overnight. 
The complete panel of gB CARs was tested in two independent donors and 
representative results shown. D. Cytolytic activity of gB CAR T cells was monitored 
using a 6hr chromium release assay. Shown are representative results for one donor. 
This assay was performed at least twice with 2 independent donors. Plots show means 
+/- SEM of triplicate wells. Statistical analysis was done using two-way ANOVA for 








Figure 3.3. CAR T cells redirected to CMV gB exhibit antigen-specific activity. A. Vector 
map of anti-gB CAR constructs designed with different spacer domains of various 
lengths. Highlighted in red are mutations introduced into the gB IgG4 CAR variant to 
reduce Fc receptor binding in vivo. B. Production of tumor necrosis factor-alpha (TNFα), 
interferon-gamma (IFNγ), interleukin-2 (IL-2) and a marker of degranulation (CD107a) 
was assessed via an intracellular cytokine-staining assay. Untransduced (UTD) T cells 
and gB CAR expressing T cells from the same donor were co-cultured with human 
glioma cell line U87 or with U87 cells transduced with gB at an effector to target ratio of 
1:1 overnight. The complete panel of gB CARs was tested in two independent donors 
and representative results are shown. C. Cytolytic activity of gB CAR T cells was 
monitored using a 6hr chromium release assay. Shown are representative results. This 
assay was performed at least twice with 2 independent donors. Plots show means +/- 
SEM of triplicate wells.   
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Figure 3.4. A. CMV-infected human foreskin fibroblasts (HFFs) were co-cultured with gB 
CAR T cells. Production of TNFα, IFNγ, and IL-2 monitored via an intracellular cytokine-
staining assay. Untransduced (UTD) T cells and gB CAR expressing T cells from the same 
donor were co-cultured with HFFs mock-infected or infected with HCMV 96 hours post 
infection at an effector to target ratio of 1:1 during overnight co-culture. This experiment 
was performed twice using a total of three independent donors. Statistical analysis was 
done using a two-way ANOVA with multiple comparisons using Tukey’s correction (* = 
p<0.05, ***= p <0.0005). B. Human foreskin fibroblasts were infected with HCMV at an 
MOI of 1:5 or mock infected. Infected cells were intracellularly stained with anti-gB 
monoclonal and analyzed by flow cytometry for gB expression over a five day time course 
post infection. Statistical analysis was done using two-way ANOVA for multiple 













































































































Figure 3.5. gB CAR T cells kill GBM cell lines (A) and tumor explants (B) cultured ex-vivo. 
A. Glioma cell lines U87 and U87gB (4hr time point) and B. ex-vivo cultured GBM tumors 
(6hr time point) were co-cultured with effector T cells at effector:target ratios ranging from 
30:1 to 1:1. Newly resected GBM tumors were cultured for up to 20 days post resection 
for these experiments. A chromium release assay was used to measure specific lysis of 
ex-vivo cultured tumors. Effector to target ratio is based on CAR + T cells and total T cell 
count was normalized among control groups. Negative controls were untransduced T cells 
(UTD) and CD19 CAR T cells. EGFRvIII CAR T cells were used as a general positive 
control for most experiments. Plots show means +/- SEM of triplicate wells. Shown are the 
results of one assay using tumor cells from three different patients co-cultured with one 





Figure 3.6. Antitumor effects of gB CAR T cells in vivo. A. Schematic representation of a 
murine subcutaneous tumor model using NOD scid gamma (NSG) mice. NSG were 
inoculated subcutaneously with 5x105 U87gB+ tumor cells (n=10 or more animals per 
group). Five days after tumor engraftment, mice were randomized based on tumor 
bioluminescence and treated with 5x106 CAR+ T cells per mouse via tail vein injection. 
The addition of untransduced T cells to the total T cell dose was used to normalize the 
total amount of T cells given per mouse. B. The predetermined endpoints were determined 
by serial caliper measurements taken at regular intervals until the tumor reached the 
endpoint of 2cm in any dimension (LxWxH) or the mouse showed signs of graft versus 
host disease (GHVD). + Indicates all mice have reached the predetermined humane 
endpoint. Each line represents the mean average of the group and standard error of the 
mean represented by the error bars. A two-way ANOVA was performed comparing 
experimental gB CAR T cells to the CD19 CAR T cell treated mice (* = p<0.05, *** = p 
<0.0005)). C. Survival based on time to endpoint of tumor-bearing mice treated with gB 
CAR T cells or CD19 CAR T cells. Kaplan-Meier curve and statistical significance between 
experimental and control groups determined using log-rank Mantel-Cox test. D. Individual 
growth curves for each mouse per group until reaching endpoint. The experiment was 
repeated twice with two independent T cell donors.  
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Figure 3.7. gB CAR T cells have anti-tumor activity against naturally-infected GBM explant 
D270. A. The human glioma xenograft explant cell line D270 was immunostained with 
anti-gB monoclonal and analyzed via flowcytometry. Human glioma cell line U87 
transduced with glycoprotein B was used as positive control. B. Immunohistochemistry 
(IHC) for CMV antigen IE1-72 on brain tissue isolated from NSG mice after intracranial 
injection of D270 cells C. Cytolytic activity of gB CAR T cells against D270 in a 6hr 
chromium release assay. Shown are representative results from one donor. This assay 
was performed at least twice with 2 independent donors. Plots show means +/- SEM of 
triplicate wells.  






















Figure 3.8. gB CAR T cells have anti-tumor activity against naturally-infected GBM explant 
D270 in vivo A. Schematic representation of a murine subcutaneous tumor model using 
NSG mice. NSG were inoculated subcutaneously with 4x105 D270 cells (n=10 per group). 
Three days after tumor engraftment and again at day ten, each mouse was treated with 
5x106 CAR+ T cells per mouse injected intravenously. N=10 animals per group unless 
otherwise noted. E. Serial caliper measurements taken at regular intervals until the tumor 
reached the end point of 2cm in any dimension (LxWxH) or showed signs of graft versus 
host disease (GHVD). Each line represents the mean average of the group and standard 
error of the mean represented by the error bars. A two-way ANOVA was performed 
comparing experimental gB CAR T cells to the CD19 CAR T cell treated mice (* = p<0.05). 
F. Individual growth curves for each mouse per group until reaching the endpoint. 
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We Can Rebuild It, We Have the Technology: Using gB CAR T Cells to 
Reconstitute HCMV Immunity 
Inherent in the design of the gB CAR lies an alternative use in the context 
of HCMV reactivation in patients recovering from allogeneic hematopoietic stem 
cell transplantation (allo-HSCT) (Full et al., 2010; Moss & Rickinson, 2005; Proff 
et al., 2018). Adoptive cell transfer (ACT) of viral-specific T cells (VSTs) to control 
viral reactivation has been tested clinically with remarkable success (Harris et al., 
2019; Papadopoulou et al., 2014; Riddell et al., 1992). These clinical trials 
demonstrate the feasibility of using ACT in controlling viral reactivation; however, 
with the exception of HIV, no clinical trials to our knowledge have reported the use 
of CAR T cells as the modality of treatment (Scholler et al., 2012). CAR T cells 
overcome a major limitation of ex vivo expanded viral-specific T cells by 
recognizing their cognate antigen in an HLA-independent fashion, thus allowing 
for the development of T cells that recognize shared and common target antigens 
on infected cells with universal application. Circumnavigating HLA-restriction 
allows for broad clinical application of virus-specific CAR T cells for patients with 
compromised or suppressed immune systems experiencing viral reactivation 
(Gandhi & Khanna, 2004; Jain et al., 2014).  
There is promising clinical evidence from testing the efficacy and safety of 
VSTs to treat a wide range of viral infections to suggest that a CAR T cell-based 
approach would also work. Unlike cancer and HIV, where most clinical 
interventions work to delay disease progression, most of the infections treated with 
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VST therapies cannot be cleared by the endogenous, unmodified immune system. 
The problem lies in the inability of the patient to develop a new immune response 
or recall from memory effectors to common pathogens, such as HCMV, Epstein-
Barr virus (EBV), and Adenovirus, after allo-HSCT (Moss & Rickinson, 2005). 
Ultimately, this becomes a clinical problem of accessibility. Rapid delivery of a VST 
or CAR T cell product may be able to suppress viral reactivation. Fortunately, there 
are a few ways to manufacture clinical products in a short amount of time (Bollard 
& Heslop, 2016). The safest approach would be to use a patient’s own T cells to 
express the anti-viral CAR construct. A highly personalized autologous T cell 
product would be safer with regard to avoiding graft versus host disease (GVHD) 
than allogenic donor-derived VSTs. Autologous T cells can be lentivirally 
transduced for stable expression or electroporated with CAR mRNA for a rapid but 
transient expression of CAR (Foster et al., 2019; Maus et al., 2013). Transient 
expression of a TCR specific to hepatitis B virus (HBV) led to a drop in HBV viremia 
in a mouse model, suggesting that mRNA transfer of TCR or CAR could be a 
feasible approach to control viral infections (Kah et al., 2017). Autologous CAR T 
cells are likely to persist in patients recovering from allo-HSCT, such that a 
preemptive infusion of anti-viral CAR T cells could avert the complications 
associated with viral reactivation. 
The second approach would be to use third-party donor T cells expressing 
anti-viral CARs. In this scenario, safety of the CAR T cell product is traded for 
convenience of utilizing a bank of “off-the-shelf” T cell products. Despite the safety 
precautions one must consider when using third-party donor T cells, there is 
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evidence to suggest that VST products can be safe (Leen et al., 2013). In a clinical 
trial using banked third-party VSTs, patients undergoing viral reactivation were 
infused with partial HLA-matched T cells. Recipients were given a T cell product if 
they shared at least one of out six potential class 1 HLA alleles. Surprisingly, no 
acute severe adverse events (SAEs) were reported after the VST products were 
administered to patients and only 2 patients out of 50 in the clinical trial developed 
de novo GHVD. Depending on the viral infection being treated, successful 
resolution from infection ranged from 66.7 % to 77.8% (Leen et al., 2013). A follow-
up clinical study using a “mini” bank of HCMV-specific T cells derived from 8 donors 
reported a 100% response rate and no SAEs associated with administration of the 
T cell product (Tzannou et al., 2019). The safety and feasibility of using a highly 
enriched anti-viral T cell product as a platform for CAR expression makes VSTs a 
convenient source for donor-derived T cells due to their reported safety. 
Additionally, VSTs as a CAR expression platform can result in the development of 
CAR T cells with multiple specificities conferred via the endogenous TCR and CAR 
that could reconstitute anti-viral immunity simultaneously against multiple viruses. 
A final note on the matter, as gene-editing technology improves the ability to make 
universal CAR T cells, the potential to generate large stocks of banked anti-viral 
CAR T cell products from third party donors and administered “off-the-shelf” at 
medical centers may be realized (Bollard & Heslop, 2016; Qasim et al., 2017; Ren 
et al., 2017).  
While the reported clinical efficacy of VSTs is promising as a modality to 
treat viral infections, the cost of the producing these cells can be prohibitory to its 
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implementation in the clinic and one must consider cost as a factor in whether a 
cell therapy is implemented to treat viral reactivation over conventional anti-viral 
drugs. One study focusing on the clinical and financial burden of HCMV 
reactivation after allo-HSCT found that 75.6% patients at risk for HCMV disease 
experienced HCMV reactivation at a median of 30 days post transplantation. 
Moreover, pre-emptive treatment of HCMV using antiviral drugs led to a mean 
increase of 13.9 days of additional inpatient hospitalization resulting in an 
estimated added cost ranging from $58,000 to $74,000 per patient (Jain et al., 
2014). Similarly, a medical center in France found that the occurrence of one or 
more HCMV reactivation incidents could raise the total cost of allo-HSCT by as 
much as 25-30% (Robin et al., 2017). While treatment of HCMV reactivation with 
antiviral drugs may be convenient, it is not without complications and toxicities. 
Acute kidney damage and myelosuppression have been reported for some 
antiviral drugs commonly used to treat HCMV diseases (Jacobsen & Sifontis, 
2010). The limited range of efficacy and continual dosing of these drugs complicate 
the clinical management of HCMV disease, which makes a compelling case for the 
use of HCMV CAR T cells or VSTs as a safer and effective alternative.  
The high response rates reported using ACT of HCMV-specific T cells 
demonstrate that reconstitution of HCMV immunity is a biological possibility. It 
remains to be determined if gB CAR T cells will have comparable clinical activity. 
HLA-independent CAR T cell recognition of the target antigen reduces the 
associated costs of making HCMV-specific T cells for specific HLA alleles. Further 
cost reduction could be found in the relatively low dose required to reconstitute 
	 68	
HCMV immunity. One study used autologous polyclonal CD8+ and CD4+ HCMV-
specific T cells with 15/18 patients responding to doses as low 1.2-116 x103cells/kg 
after allo-HSCT (Feuchtinger et al., 2010). Allogeneic CD8+ HCMV-specific T cells 
similarly eliminated HCMV infection in 8/9 patients with doses ranging from 1.2-33 
x103 cells/kg (Cobbold et al., 2005). Independent of the T cell source, the low dose 
required to eliminate HCMV infection could translate into lower manufacturing 
costs. Additionally, as the cost of CAR T cell therapies is reduced by improvements 
to gene-editing, gene transfer technologies, and manufacturing, VST therapies can 
be implemented at medical centers as a safe and effective alternative to toxic 
antiviral drugs (Manufacturing reviewed in Levine, Miskin, Wonnacott, and Keir 
(2017)).  
 
A Dream Antigen for a Sleeping Virus: Redirecting CAR T Cells to HCMV 
antigen US28    
While the focus of this body of work is based on targeting gB, the breath of 
potential targets found within the HCMV genome should be taken into 
consideration (Gandhi & Khanna, 2004). Another HCMV antigen that can be 
targeted via CAR T cells is the HCMV-encoded chemokine receptor US28. US28 
is a viral G protein-coupled receptor (vGPCR) that shares homology to human 
CCR1, CCR2, CX3CR1 and provides the virus the ability to scavenge host-derived 
signals with high promiscuity (Lee, Chung, & Lee, 2017). Studies into the function 
of US28 found that this vGCPR assists in the dissemination of HCMV by promoting 
cellular migration via chemotaxis (Streblow et al., 1999). Another report suggested 
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that US28 is a potential viral oncogene that confers an angiogenic phenotype and 
promotes tumor formation in cells stably expressing US28 (Maussang et al., 2006). 
Given these oncogenic properties, it is no surprise that US28 is expressed GBM 
(Dziurzynski et al., 2011; Soroceanu et al., 2011). Ectopic expression of US28 in 
primary GBM tumors leads to an invasive phenotype and increase of angiogenic 
activity via VEGF secretion (Soroceanu et al., 2011). Targeting approaches using 
a US28-specific nanobody resulted in a delay in tumor growth in a murine 
orthotopic tumor model of GBM (De Groof et al., 2019; Heukers et al., 2018). Unlike 
gB, expression of US28 has been reported in both lytic and latently infected cells 
(Cheung, Abendroth, Cunningham, & Slobedman, 2006; F. D. Goodrum, Jordan, 
High, & Shenk, 2002; Krishna et al., 2017). As a potential CAR target, US28 could 
pose toxicities by killing latently infected CD34+ bone-marrow progenitor cells and 
CD14+ monocytes that carry the HCMV (Sinclair & Sissons, 2006). Alternatively, 
depending on the distribution of HCMV among the CD34+ bone-marrow progenitor 
cells, therapeutic clearance of the HCMV reservoir could be achieved with 
manageable toxicities using US28-specific CAR T cells. US28 helps maintain 
HCMV latency, rendering latently infected cells susceptible to CAR T cell killing if 
expressed on the surface (Humby & O'Connor, 2015). Furthermore, loss of US28 
expression results in the initiation of lytic infection and expression of a large subset 
of antigens, many of which can be detected by CD8+ T cells primed to HCMV 
antigens presented on class I HLAs (Krishna et al., 2016). The CD34+ 
compartment displays different subsets of cells that may not be amenable to 
HCMV replication and thus may be spared by US28-specific CAR T cells, 
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suggesting negligible US28-CAR mediated toxicities (F. Goodrum, Jordan, 
Terhune, High, & Shenk, 2004). gB and US28 represent two out of many potential 
CAR targets found within the large genome of HCMV. The expression patterns of 
these two antigens delineate potentially different levels of toxicities and therapeutic 
outcomes. This broadens the pool of potential targets that can be targeted with 
CAR T cells for GBM immunotherapy. 
 
Getting to the Root of the Problem: Using gB CAR T Cells to Target Glioma 
Cancer Stem Cells  
 The emergence of the concept of the cancer stem cell (CSC) to explain the 
ability of a tumor remerge after treatment has gained traction in cancer research. 
CSCs constitute a small and rare fraction of the total tumor cell population but 
possess high proliferative capacity and self-renewal capability (Ma et al., 2018). 
Given these tumor re-initiating properties, therapeutically targeting CSCs would be 
beneficial to patient outcomes. Standard cancer therapies indiscriminately kill 
tumor cells and normal cells but do not result in total elimination of these tumor-
initiating cells. In GBM, glioma CSCs (gCSCs) have been traditionally defined by 
CD133+ antigen expression; however, additional antigens, such as Notch1, SOX2, 
Oct4, and Nestin have also been used to define these cells. A series of reports 
have suggested that HCMV is enriched in the gCSC population or may directly 
induce a stem-like phenotype in infected glioma cells (Fiallos et al., 2014; Fornara 
et al., 2016; Soroceanu et al., 2015). These observations suggest that an HCMV-
specific CAR T cell would selectively deplete tumor-reinitiating gCSCs and reduce 
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the likelihood of tumor reoccurrence. Other groups have reached similar 
conclusions on how immunological targeting of HCMV in GBM may lead to durable 
responses in patients with GBM (Rahman et al., 2019). It is worth noting that 
EGFRvIII expression has also been linked to gCSCs, but clinical use of an 
EGFRvIII CAR did not result in a halt of disease progression (Morgan et al., 2012; 
O'Rourke et al., 2017).  
 
Tumor Associated Macrophages: GBM’s Workhorse and HCMV’s Trojan 
Horse  
 One of the interesting features of re-directing T cells to HCMV antigens is 
the possibility that gB CAR T cells could kill tumor-supporting macrophages. A 
large fraction of the GBM tumor mass can be attributed to myeloid cells, specifically 
tumor-associated macrophages (TAMs) and microglia (Graeber, Scheithauer, & 
Kreutzberg, 2002; Hussain et al., 2006). Similarly, when the immune infiltrate of 
GBM tumors was analyzed after treatment with	 neoadjuvant nivolumab, the 
myeloid lineage was found to be the most abundant non-tumor cell (Schalper et 
al., 2019). TAMs account for up to 30% of a GBM’s total tumor mass and can 
subvert anti-tumor T cell responses via secretion of immune-inhibiting cytokines 
contributing to the immunosuppressive microenvironment of GBM (Wurdinger, 
Deumelandt, van der Vliet, Wesseling, & de Gruijl, 2014). While generally regarded 
as tumor supporting, TAMs can be re-educated to have antitumor activity. In a 
murine model of pancreatic ductal adenocarcinoma, the use of an anti-CD40 
agonistic monoclonal antibody in combination with gemcitabine lead to tumor 
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regression by re-educating macrophages to develop M1 anti-tumor phenotype 
(Beatty et al., 2011). Systemic depletion of T cell subsets did not abrogate the 
treatment effect in tumor bearing mice, suggesting that macrophages possess 
tumoricidal activity independent of T cell help. The phenotypic plasticity displayed 
by TAMs can provide an antigen-independent mechanism of tumor killing that can 
complement CAR T cells armed with a narrowly defined specificity.  
TAMs could also account for the presence of HCMV in many GBM tumors. 
While investigating the origin of GBM TAMs, one group found that most of TAMs 
originated from the bone marrow and are not tissue-resident microglia cells (Muller 
et al., 2017). This observation is interesting when paired with reports 
demonstrating that myeloid cells derived from HCMV-infected CD34+ progenitors 
are the only cells permissive for HCMV reactivation and replication in the periphery 
(Taylor-Wiedeman, Sissons, Borysiewicz, & Sinclair, 1991). In light of these 
reports, one can speculate that HCMV infected bone marrow-derived 
macrophages serve as a “Trojan horse” for HCMV to enter tumor sites and could 
explain the large tropism of this virus for many unrelated malignancies in addition 
to GBM. Once HCMV-infected monocytes enter the tumor microenvironment, the 
virus is allowed to spread primarily via a cell-to-cell process mediated in part by gB 
(Isaacson & Compton, 2009; Navarro et al., 1993). Experimental evidence to 
support the “Trojan horse” hypothesis comes from a report that identified TAMs 
and gCSCs as the cells within GBM tumors that harbor HCMV genomes. 
Moreover, when these GBM TAMs were characterized, they displayed an M2 
immunosuppressive phenotype that was correlated with expression of HCMV viral 
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IL-10 (vIL-10) homologue (Dziurzynski et al., 2011). The immunosuppressive 
microenvironment of GBM provides a viral sanctuary for HCMV to replicate without 
fear of clearance from the immune system. The onco-modulatory contribution of 
HCMV proteins to GBM increases tumorigenicity, which results in an unlikely 
symbiotic relationship between HCMV and GBM (reviewed in (Dziurzynski et al., 
2012)). As a therapeutic intervention, CAR T cells simultaneously targeting both 
gCSCs and TAMs could result in a lethal blow to the GBM support system; the 
roots and soil that permit GBM to persist could be rendered so inhospitable after 
anti-gB CAR T cell treatment that tumor reoccurrence may be delayed or averted 
entirely. However, if TAMs cannot be depleted, they could be skewed to an anti-
tumor phenotype. As demonstrated by (Pyonteck et al., 2013), pharmacological 
inhibition of the colony stimulating factor-1 receptor (CSF1-R) in a murine glioma 
model resulted in a reduction of TAMs with M2-like phenotype and delayed GBM 
tumor growth. This would suggest that a similar depletion or modulation of glioma-
associated macrophages would confer a survival benefit to patients with GBM. 
Lastly, GBM tumors undergo tumor evolution from the initial diagnosis to 
recurrence. Nearly half of GBMs that have been molecularly subtyped as one 
subtype often morph to another and this evolution results in an altered immune-
infiltrate (Q. Wang et al., 2017). Particularly, loss of the NF1 tumor suppressor 
gene in the mesenchymal subtype of GBM results in a marked increase of M2 
macrophages that render GBM tumors radio-resistant.  
These studies underscore the importance of TAMs as immunotherapy 
targets. As mentioned before, macrophages possess T cell-independent anti-
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tumor activity (Beatty et al., 2011; Pyonteck et al., 2013). Promoting anti-tumor 
macrophage phenotypes or depletion of M2 macrophages would provide a general 
mechanism of anti-tumor activity and go beyond the limited scope of targets that 
CAR T cells can recognize on the tumor. 
 
Modulation of HCMV Antigen Expression via Epigenetic Modulation of HCMV 
Latency 
Viral latency allows virus to persist in hosts with minimal detection by the 
immune system. Because viral replication is not occurring, even the best anti-viral 
therapies fail to prevent eradication of the viral reservoir. This is perhaps best 
exemplified in the treatment of HIV with ART and the daily dosage required to keep 
the virus latent. However, if a virus could be driven out of latency, then therapeutic 
viral clearance can be achieved. This approach is being evaluated to clear HIV out 
of latency in combination with HIV-specific T cells, a “kick-and-kill;” strategy (S. H. 
Huang et al., 2018).  One approach to drive a virus out of latency is through the 
use of HDAC inhibitors (HDACi). As it relates to HCMV, one report demonstrated 
that a class II HDACi was sufficient to trigger transient lytic infection and make cells 
harboring latent virus susceptible to killing by HCMV-specific T cells (Krishna et 
al., 2016). As a parallel, anti-gB CAR T cells could demonstrate similar activity on 
HDACi-treated tumor cells to drive expression of gB. The molecular events that 
lead to lytic infection are tied to expression of the HCMV immediate early 1 and 2 
(IE1 and IE2) gene products. The major immediate early promoter (MIEP) controls 
expression of IE1 and IE2 and during latency is kept in a repressive chromatin 
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state by HDAC3 activity (Murphy, Fischle, Verdin, & Sinclair, 2002). Specific 
inhibition of HDAC3 could therefore jumpstart HCMV lytic gene expression, 
including expression of gB.   
If HDACi approaches do not work, targeting the regulators of HCMV latently 
could be an alternative approach. HCMV US28 expression on latently infected 
cells has been reported to help maintain MIEP in a repressive state. This activity 
has led to the development of therapies that seek to block the activity of US28 to 
eradicate the HCMV reservoir (Elder & Sinclair, 2019). A US28-specific nanobody 
can stop the constitutive activity of US28 by blocking ligand binding and lead to 
lytic gene expression (Heukers et al., 2018). As previously discussed, surface 
expression of US28 makes this HCMV antigen a potential CAR target. The ability 
of CAR T cells to home to sites of antigen expression could lead to direct 
eradication of the HCMV latent reservoir. Alternatively, the ability of T cells to 
trogocytose and deplete US28 on latently infected cells could also trigger lytic gene 
expression (Hamieh et al., 2019). CAR T cells simultaneously targeting both US28 
and gB would work on distinct phases of the HCMV life cycle. Additionally, blocking 
of US28 activity via nanobody or CAR could sensitize HCMV infected cells to killing 
via gB expression or other intracellular antigens such pp65 or IE1 that T cells are 
primed to detect. 
 
gB CAR T cell Associated Toxicities: Known Knowns and Known Unknowns  
 Genetically re-directing T cells to new specificities can be fraught with 
danger, resulting in immune destruction of non-malignant tissues that express the 
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target antigen. HCMV and other viral-associated tumor antigens may offer a 
greater safety profile than traditional TAAs derived from self-antigens as viral 
antigens are intrinsically foreign to the patient’s immune system. One can draw 
inferences from the natural immune response to HCMV and how this could predict 
safety of anti-gB CAR T cells in the clinic. Acute infection with HCMV leads to 
robust cellular and humoral immune response in an infected host, typically with no 
development of overt symptoms of infection. Resolution of HCMV infection leads 
to a latent infection with no associated autoimmune disease. The human host can 
develop a robust immune response to HCMV and its gene products, as they are 
foreign antigens that are readily recognized by the immune system, thus breaking 
immunological tolerance. For this reason, humoral and cellular responses to 
HCMV can be readily detected in patients. This feature is reflected in the 
construction of our gB CAR. The scFv used to generate our gB CAR was derived 
from a healthy human donor that experienced CMV infection and developed 
antibodies to gB (Ohlin et al., 1993).  
The safety of gB CAR T cells draws inferences based on the typical 
mechanisms of how a T cell or an antibody-producing B cell recognizes antigen. 
CAR T cells sense antigen in an HLA-independent manner and this could be a 
source of unexpected toxicities. As mentioned earlier, trastuzumab (Her2 mAb) 
does not cause lung toxicities; however, when the same Her2 scFv was used in a 
CAR construct, the first and only patient treated experienced lethal acute lung 
toxicities (Morgan et al., 2010). Following this logic, similar toxicities can occur due 
to the atypical recognition of gB antigen on normal tissue by anti-gB CAR T cells 
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that would be undetectable if the anti-gB targeting occurred via an antibody-
dependent mechanism. Experimentally, the increased sensitivity of CAR T cells to 
low levels of antigen has been demonstrated when comparing BiTE molecules to 
CAR T cells bearing the same scFv (Stone et al., 2012). The degree of sensitivity 
CAR T cells have towards their cognate antigens has been the subject of 
speculation. An initial determination of the sufficient amount of molecules needed 
to trigger cytolytic function of an anti-CD20 CAR T cell was estimated to be 
approximately 200 CD20 molecules on the surface of the target cell (K. Watanabe 
et al., 2015). Refinement in tools used to measure antigen density has shown 
thatin some cases with optimized CARs, less than 100 molecules of CD19 or CD20 
are sufficient to trigger T cell lysis of a tumor cell (Nerreter et al., 2019). The 
exceedingly low levels of antigen needed for CAR T cells to kill a target cell may 
uncover toxicities on normal tissues, which may lead to pathology not typically 
associated with HCMV gB-specific antibodies. 
 Another factor is the possibility that anti-gB CAR T cells could cross react 
with self-antigens that have similar epitopes as the CAR or other herpes virus 
family gB antigens that share a highly conserved protein structure (Heldwein et al., 
2006). While these safety concerns highlight unknown toxicities, known toxicities 
can occur in cells that harbor the HCMV reservoir. CD34+ myeloid progenitor cell 
are a well-established reservoir of HCMV (Sinclair & Sissons, 2006). Reports 
profiling expression of HCMV genes in latently-infected CD34+ myeloid 
progenitors do not report gB/UL55 gene expression, as it is considered a marker 
of early-to-late productive lytic infection (Cheung et al., 2006; F. D. Goodrum et al., 
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2002; Stern & Slobedman, 2008). The shift from HCMV latency to reactivation 
occurs in monocytes undergoing differentiation at which point expression of gB 
can be detected (Soderberg-Naucler et al., 2001). Even if gB CAR T cells were to 
eliminate all HCMV harboring monocytes, this would not result in a monocyte 
deficiency. One estimation found that the frequency of peripherally latently-
infected mononuclear cells from 12 patient-derived samples was approximately 
0.004% to 0.01% of the total cell population (Slobedman & Mocarski, 1999). This 
exceedingly rare population of HCMV-infected cells in an immune-competent host 
would predict negligible “off-tumor, on-target” toxicities.  
 
CAR T Cells Redirected to HCMV May Have Superior Anti-Tumor Activity 
than Ex-vivo Expanded HCMV-specific T Cells  
The success of ACT therapies can depend on the quality of the T cell 
product. One of the features distinguishing CD19BBz CAR T cells from those 
bearing CD28 costimulation is the enrichment of the central memory (CM) 
phenotype (Kawalekar et al., 2016). Delving deeper, one group investigated the 
anti-tumor properties of different T cell memory subsets and established that a less 
differentiated T cell has a higher proliferative capacity and this correlated with 
persistent anti-tumor activity (Gattinoni et al., 2011). As it relates to HCMV-specific 
T cells, one must consider the memory state of the antigen-specific pool, especially 
if they are using in ACT therapies with ex vivo expanded HCMV-specific T cells. 
Chronic infection of HCMV leads to effector memory differentiation of T cells due 
to prolonged antigen exposure (Pardieck, Beyrend, Redeker, & Arens, 2018; Vieira 
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Braga, Hertoghs, van Lier, & van Gisbergen, 2015). Clinical trials using ACT of 
HCMV-specific T cells to treat GBM may have resulted in poor clinical outcomes 
perhaps due, in part, to the differentiation state of the T cell product (Ahmed et al., 
2017; Ghazi et al., 2012; Schuessler, Smith, et al., 2014). The series of work using 
dendritic cell vaccines pulsed with pp65 have been promising in that they generate 
poly-functional T cells (Reap et al., 2018). An alternative approach to overcome 
this inherent barrier of using endogenous HCMV-specific T cells is to re-direct T 
cells using a CAR. Differentiation data from the gB CAR T cells demonstrate that 
anti-HCMV CAR T cells bear a central memory phenotype. A report investigating 
tumor-infiltrating T cells found HCMV-specific T cells present in GBM tumors; 
however, these cells displayed a tolerized and exhausted phenotype (Bahador et 
al., 2017). Moreover, in a clinical trial that used ex vivo expanded CMV-specific T 
cells to treat GBM, TILs were analyzed from a patient that developed progressive 
disease 4 months after treatment and the HCMV-specific T cells displayed a high 
degree of exhaustion makers. Nearly half of the CMV-specific T cells were unable 
to respond to stimulation (Schuessler, Smith, et al., 2014). These studies would 
suggest that endogenous T cells primed to HCMV via infection recognize HCMV 
antigens in GBM tumors but do not impact tumor growth due to an exhausted 
phenotype. CAR T cells re-directed to HCMV may fair a bit better in tumor 
microenvironments due to the contribution of the CAR co-stimulatory domain, 




Follow Up studies 
This body of work has yielded a new CAR target for the treatment of GBM, yet 
some questions remain that require more thorough investigation. The remaining 
section will outline experiments that will help improve the clinical implementation 
of anti-gB CAR T cells against GBM. 
 
Experimental Determination of gB CAR T Cell Safety and Toxicities 
The section on safety considerations outlines the natural history and 
immune response to CMV as predictors of the safety profile of gB CAR T cells. 
Experimentally, the safety of profile of gB CARs can be tested using a panel of 
primary human cells representing various tissues and organs. This panel has been 
previously been used to determine the on-target, off-tumor toxicities of an affinity-
tuned CAR T cells re-directed to either EGFR or HER2 (Liu et al., 2015). Particular 
emphasize could be placed on cells deemed to be reservoirs of HCMV, such as 
CD34+ myeloid progenitor cells/HPSC (Sinclair & Sissons, 2006). A useful model 
to guide the development of our toxicity models is a report on CAR T cells re-
directed to CD30 for	Hodgkin's and non-Hodgkin's lymphomas. Due to potential 
“on-target, off tumor” complications, this study focused on the potential for toxicities 
in CD30+ HPSCs. Despite CD30 expression, HSPCs were not killed by CD30 CAR 
T cell due, in part, to lower levels of target expression that was insufficient to trigger 
CAR T cell killing. Additional mechanisms of resistance stems from HSPCs 
expressing SP6/PI-9 serine proteases that inactivate granzyme B-mediated killing 
(A. A. Hombach et al., 2016). The resilience of HPSCs to CD30 CAR T cell-
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mediated killing may bode well for the safety of gB CAR T cells. An experiment 
that will directly address this question is ex vivo co-culture of CD34+ HPSCs from 
HCMV+ donors with gB CAR T cells. The degree and magnitude of toxicities 
against HPSCs could be inferred from this experiment. Additionally, the normal cell 
panel reported by Liu et al. could be used to detect killing of normal tissues that 
express antigens that may cross-react with the epitope of ITC52 scFv-based gB 
CAR (Liu et al., 2015). Due to the broad tropism of HCMV, it is possible that gB 
CAR T cells may kill HCMV-infected cells of various tissue origins; however, 
clinical presentation of these toxicities may not differ from that of endogenous T 
cell mediated killing of infected cells during HCMV acute infection. 
 
Improving the Sensitivity of gB CAR T Cells to Low Levels of Antigen 
Expression 
Low levels of gB antigen expression on GBM tumors could limit the efficacy 
of gB CAR T cells. Despite optimization of the hinge region to improve cytokine 
production in vitro, these modifications may not be enough to trigger CAR T cell 
effector function if gB antigen on primary GBM is found below an activation 
threshold (A. A. Hombach et al., 2016; K. Watanabe et al., 2015). Fine-tuning the 
signal strength mediated by CAR signaling domains may be an alternative 
approach to improving gB CAR T cell function. Sensitization of a CAR T cell to 
target antigen can be achieved by the incorporation of additional ITAM domains 
into the CD3z chain domain of first generation CD19 CAR construct. Typical CAR 
constructs include 3 ITAM domains; however, with the addition of more ITAMs, 
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CD19 CAR T cells were able to recognize CD19low-expressing targets (J. R. 
James, 2018). This modification could be introduced into the design of the second 
generation gB CAR constructs to improve the sensitivity to gB antigen. The 
sensitivity of gB CAR T cells with additional ITAMs can be tested by dosing gB 
antigen into target cells via mRNA electroporation. Both cytotoxicity assays and 
cytokine release assays can be used as readouts to determine if additional ITAMs 
improve the sensitivity of gB CAR T cells. A variation of this experiment was 
reported for HER2 affinity-tuned CAR T cells. Dosing of increasingly low amounts 
of HER2 mRNA into target cells was sufficient to trigger CAR T cell degranulation 
in a HER2-specific CAR T cells. The addition of ITAMs or a different signaling 
domain can be compared using the experiments outlined in (Liu et al., 2015).  
Studies comparing the anti-tumor function of CAR T cells that incorporate 
either the CD28 or CD137 (4-1BB) co-stimulatory domain rely upon models where 
target antigen expression is well above the threshold needed to trigger CAR T cell 
function. In tumor models where antigen is limiting due to low expression, 
incorporation of a CD28 co-stimulatory domain could potentially improve sensitivity 
and anti-tumor function of CAR T cells due to stronger signal provided by CD28 
and less frequent engagement with target antigen (Salter et al., 2018; Walker et 
al., 2017). CAR T cells can diminish the level of target antigen on a tumor cell via 
the process of trogocytosis. This mechanism of lowering antigen density was true 
for both CD19 CAR using either a CD28 or a 4-1BB co-stimulatory domain. 
However, it was only in the cohort of tumor bearing mice treated with CD1928z 
CAR T cells that clearance of CD19low antigen tumors was observed (Hamieh et 
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al., 2019). These modifications underscore the importance of fine-tuning of signal 
strength for the particular antigen being targeted, as many of the reports 
demonstrating the superior anti-tumor activity of CAR T cells bearing the 4-1BB 
co-stimulatory domain are based on tumor models where antigens were expressed 
at normal levels.	
 
Broadening the Range of Clinical Strains of CMV Covered by gB CAR T Cells  
Immunological pressure exerted upon any epitope could result in the 
development of escape variants. This problem is particularly pronounced when 
targeting viral antigens. The scFv of ITC52 used to develop this gB CAR 
recognizes the AD-1 epitope of gB, which is highly conserved among HCMV 
strains. Mutations introduced into the AD-1 domain resulted in loss of infectious 
virus particles produced, suggesting that viral fitness is compromised if this domain 
undergoes mutations (Britt, Jarvis, Drummond, & Mach, 2005). Factoring the 
mutational constraints that gB AD-1 can handle, the likelihood of encountering 
escape variants is greatly diminished for gB CAR T cells targeting this epitope. 
However, additional epitopes within gB have been reported along with new human 
donor derived scFvs that recognize additional antigenic domains (Ohlin & 
Soderberg-Naucler, 2015). I have generated a new set of gB CAR constructs 
based on the SM5-1 scFv that recognizes the AD-5 domain of gB (Potzsch et al., 
2011). Other groups have published abstracts using the SM5-1 scFv in their gB 
CAR construct, indicating that this scFv can be used to re-direct CAR to gB (Olbrich 
et al., 2020). A tandem-CAR design (i.e. tan-CAR) approach could be used to 
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target gB with a two-fold benefit. The use of two scFvs that recognize gB will 
reduce the likelihood of a HCMV strain developing two simultaneous escape 
mutations (Grada et al., 2013). The second benefit would be an improvement in 
the molecular avidity of a gB CAR molecule for gB by providing two points of 
contact and, as a result, could sensitize gB CAR T cells to low levels of gB antigen 
presumed to be found on GBM tumors. 
 
Of Mice and Non-Human Primates: Animal Models to Test Control of HCMV 
Reactivation by gB CAR T Cells 
Many of the experiments designed to test the anti-tumor function of gB CAR 
T cells can be translated to the potential use of gB CARs in the context of HCMV 
reactivation. HCMV is a species-specific virus and cannot infect non-human cells, 
leaving no viable in vivo infection model for HCMV. However, the recent 
development of a humanized bone liver thymus (BLT-NSG) mouse model can now 
be used to interrogate the in vivo function gB CAR T cells (Crawford et al., 2017). 
NSG mice engrafted with human donor bone marrow, liver, and thymus develop a 
normal immune system capable of mounting an immune response comparable to 
that seen in human hosts. The benefit of an in vivo infection model would be two-
fold. First, one could study the ability of gB CAR T cells to control HCMV in the 
context of chronic infection and the persistence of gB CAR T cells. Secondly, 
toxicities associated with CD34+ progenitor cells could be evaluated in a dynamic 
model of HCMV latency if the BLT model reproduces human HCMV latency. 
Simpler models of HCMV reaction have also been reported. NSG mice engrafted 
	 85	
with only human CD34+ progenitor cells give rise to monocytes capable of carrying 
latent virus (Crawford et al., 2019). The degree of anti-viral activity gB CAR T cells 
have against HCMV infection can be measured by the genomic copies of the virus 
found in the mouse liver and spleen. A reduction in HCMV genome copies/ μg of 
DNA in these organs could signify anti-viral gB CAR T cell activity (Crawford et al., 
2019).  
Large vertebrate animal models could be more predictive of clinical 
outcomes in humans. Rhesus macaques have a species-specific CMV (RhCMV) 
that closely mimics the biology of HCMV (Powers & Fruh, 2008). The similarity 
between these two viruses also extends to the high degree of amino acids 
conservation of their respect gB antigen (Kravitz, Sciabica, Cho, Luciw, & Barry, 
1997). Of note is a report demonstrating antibodies generated against the human 
gB can cross react with RhCMV gB (Kropff & Mach, 1997). One of the mAbs tested 
for cross reactivity is the mouse mAb 27-287 that can detect both HCMV and 
RhCMV gB. mAb 27-287 recognizes the AD-1 region of gB and shares a similar 
epitope with the ITC52 human mAb used to generate my gB CAR. This would 
suggest that the ITC52-based gB CAR could also cross react with the RhCMV gB 
and be used in rhesus macaque models of CMV reactivation. Gene transfer of 
CAR constructs into rhesus macaque T cells has been previously reported, 
allowing for direct testing of the anti-viral activity of gB CAR T cells (Taraseviciute 
et al., 2018). Experimental determination of cross-reactivity could be tested by 
ectopic expression of RhCMV gB in human target cells and measuring cytotoxic 




The primary goal of this study was to test the hypothesis that human 
cytomegalovirus is a viable target for CAR T cells in GBM. The high prevalence of 
the virus in GBM tumor samples and high immunogenicity make it an attractive 
tumor target. Moreover, the immune systems’ ability to recognize and mount an 
immune response to many of the gene products found in the HCMV genome 
provide an opportunity to generate epitope spreading. Induction of epitope 
spreading is a highly desirable feature of cancer immunotherapies and may help 
to overcome the antigen heterogeneity found within tumors. 
The gB CAR detailed in this thesis serves as a prototype for further design 
improvements. HCMV expresses other surface antigens that can also be detected 
with CAR T cells and targeted with or instead of gB. Perhaps the most promising 
feature of a gB CAR is the many indications this CAR may treat. In addition to 
GBM, HCMV has been detected in breast cancer, colorectal cancer, and low-grade 
gliomas.  However, the most direct application of a gB CAR T cells would be in the 






 “Illness is the night side of life, a more onerous citizenship. Everyone who is born 
holds dual citizenship, in the kingdom of the well and in the kingdom of the sick. 
Although we all prefer to use the good passport, sooner or later each of us is 
obliged, at least for a spell, to identify ourselves as citizens of that other place.” 
 
― Susan Sontag, Illness as a Metaphor  
 
 
 As Susan Sontag reflected on the duality of wellness in her essay Illness as 
a Metaphor, she highlighted the human attributes we attach to diseases due to 
lack of understanding of a disease (Sontag, 1979). Cancer, perhaps the most 
mysterious illness at the time aptly fit the metaphor of the dual passport Sontag 
described. At the time of her writing, clinicians and cancer biologists were only 
starting to understand the molecular mechanisms that drive cancer. The work of 
Bishop and Varmus in the 1970s began to illuminate the oncogenic origins of 
cancer. Their seminal work lead to the discovery that the very genes that can cause 
cancer are sewn into our genome (Stehelin et al., 1976). Given enough time, one 
of the cells that constitutes our being could undergo cellular transformation and we 
would “identify ourselves as citizens of that other place” (Sontag, 1979). But 
genome-derived oncogenes do not tell the whole story, as tumor-associated 
viruses in their quest to replicate will also turn on or inactivate gene products that 
can initiate the process of tumorigenesis (Krump & You, 2018). In the decade that 
followed the works of Bishop and Varmus, reports of a handful of patients 
presenting with a rare malignancy and a dysfunctional immune system marked 
some of the first cases of HIV/AIDS. As it later became clear, the rarely seen 
Kaposi’s sarcoma was allowed to manifest when HIV had ravaged the patient’s 
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immune system. The culprit virus, KSHV, unchecked by an active immune system 
was allowed to transform infected cells unabated. KHSV is just one of a handful of 
tumor-associated viruses that account for up to 20% of all human cancers (Krump 
& You, 2018). The high risk of viral-associated malignancies in patients with 
HIV/AIDS underscores the importance of the immune system for keeping some 
cancers at bay (Shiels & Engels, 2017). In the later end of the decade, the first 
iteration of what would become a CAR was first published (Gross, Waks, & Eshhar, 
1989). Advances in understanding T cell biology led to improvements upon the 
CAR design, which eventually led to the approval of the first gene-therapy in the 
United States for CAR T cells targeting CD19 in ALL (Maude et al., 2014).  A 
historical perspective is warranted to reflect on where cancer immunotherapy has 
been and where it is going. Gene editing technologies, such as CRISPR, have 
made genetic manipulation of cells a routine laboratory procedure. First-in-human 
trials using CRISPR-edited T cells demonstrated that gene-edited T cells can be 
safely administered to patients (Stadtmauer et al., 2019). New reports that provide 
mechanistic insights into new ways to augment the anti-tumor function of T cells 
are published every day. However, despite the optimistic outlook of CAR T cell 
technology in treating human diseases, it is constrained by a fundamental problem: 
how to distinguish what is safe to target on a cancer cell and what is not?  
  To the cancer immunotherapist looking for a tumor-associated antigen to 
target, viral antigens represent a treasure trove of potential targets. The 
association of HCMV with GBM represents an unlikely solution to the 
immunotherapist seeking to find an antigen unique to GBM and not on normal cells 
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(C. S. Cobbs et al., 2002). In the 15 years that have passed since the initial 
publication that defined the standard of care for GBM, no other clinical intervention 
has made a meaningful difference in the prognosis of patients with GBM (Stupp et 
al., 2005). This body of work is based on the controversial presence of HCMV in 
GBM. Methodological approaches undertaken by different labs to detect HCMV in 
GBM tumors have yielded divergent results. The robustness by which other tumor 
causing viruses can be found in tumors cannot be said for HCMV and GBM 
(Dziurzynski et al., 2011). Nevertheless, the foreign and highly immunogenic 
nature of the virus to the human immune system that made it the interest of 
different research groups hoping to leverage the presence of HCMV in GBM as a 
way to target GBM. And it is only now with the advent of CAR technology that a 
viral antigen can be a shared tumor antigen. CAR T cells bypass HLA-mediated 
presentation of antigens that made a viral epitope unique to that patient’s HLA.  
 Robert Gallo’s recounting of his search and discovery of the first human 
retrovirus to cause cancer parallels the story of HCMV and GBM. Prior to the 
discovery of human T-lymphotropic virus (HTLV-1), the search for human tumor 
retroviruses proved to be a fruitless endeavor, fraught with many false positives. 
The discovery of HTLV-1 was made possible by advances in technology that were 
able to sensitively probe for retroviral mRNA and developments in methods to 
culture human T cells (Gallo, 2005). Similarly, the confluence of fortuitous 
discoveries may be required to settle the story of HCMV and GBM. The parable of 
a group of blind men trying to describe an elephant comes to mind. 
Multidisciplinary approaches have yielded different insights in the biology of HCMV 
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in GBM but the whole image remains elusive. Is this association real, and if so, 
would it have a clinical impact as a target for patients with GBM? This body of work 
adds immunological evidence to the association of HCMV and GBM. Pursuing 
HCMV as a tumor antigen is a risky undertaking but, if successful, HCMV’s gB can 
now be added to the arsenal of antigens that can be safely targeted on a tumor. 
GBM’s high antigenic heterogeneity poses the greatest challenge for the 
application of CAR T cell therapy (Brown et al., 2016; O'Rourke et al., 2017). A 
malignant Hydra of Greek mythology: for each tumor cell clone eliminated by a 
CAR T cell, another clone impervious to CAR T cell recognition will take its place. 
As intractable as GBM may seem be to clinical intervention, CAR T cells pose a 
formidable challenge. Dynamic, expanding, and adapting to an ever-shifting foe, 
the “living drugs” that CAR T cells constitute may eventually fare better than other 
forms of cancer treatment. Each refinement upon a CAR’s design and 
augmentation in the antitumor activity of a T cell chips away at the edifice that 
tumors represent.   
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